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Summary.-Part I of this report appeared in the previous issue (Br. J. Cancer (1976)
34,585), and discussed the design of randomized clinical trials. Part II now describes
efficient methods of analysis of randomized clinical trials in which we wish to com-
pare the duration of survival (or the time until some other untoward event first
occurs) among different groups of patients. It is intended to enable physicians
without statistical training either to analyse such data themselves using life tables,
the logrank test and retrospective stratification, or, when such analyses are presented,
to appreciate them more critically, but the discussion may also be of interest to
statisticians who have not yet specialized in clinical trial analyses.
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STATISTICAL NOTES FOR PART II
ANALYSIS
16.-General principles
Some of this introduction recapitulates
text from Part I.
Many clinical trials compare survival
duration among cancer patients randomly
allocated to different treatments. There has
been much investigation in the statistical
literature of possible ways of interpreting
the data from such trials, the surprising
outcome of which has been the discovery
that 2 techniques (life table graphs and
logrank P-values), which are so simple that
they are easily mastered by non-statisticians,
are commonly more accurate and more
sensitive than any of the elaborate alter-
natives that have been considered. Part II
of this report now describes these 2 tech-
niques in sufficient detail for them to be
performed entirely without statistical guid-
ance. Inessential notes on statistical details
are relegated to the end of the text, and
should be ignored by most readers.
If the course of the disease is very rapid
(e.g. acute liver failure) and it is unimportant
whether a dying patient lives a few days
longer or not, a count of the numbers of
deaths and survivors on each treatment is
all that is required. However, if (as with
most forms of neoplastic disease) an appreci-
able proportion of the patients do eventually
die of the disease, but death may take some
considerable time, it is possible to achieve
a more sensitive assessment of the value of
each treatment by looking not only at how
many patients died but also at how long
after entry they died.
You can best learn statistical methods
by applying them to data which interest
you. If you have some data to interpret,
then we hope that, when you have read
this paper and applied it to your data,
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you will feel that the methods it describes
are straightforward and that the use of
them has simplified your data and helped
you understand them. However, if you
do not have any such data to interpret,
perhaps you should not study the techni-
cal parts of this paper carefully, as
attempting to learn the details of statisti-
cal methods in the hope of applying them
at some vague date in the future usually
produces confusion.
In Part II of this article, the first
few sections describe how time to death
may be analysed, ignoring entirely all
assessment of the quality of life. The
methods described, however, are equally
useful for analysing time to some other
first event; for example, in clinical trials
of solid tumour therapy, a separate
analysis of time from entry to first local
recurrence may be of interest, or perhaps
a separate analysis of time from entry
to first metastatic spread. In later sec-
tions, we describe the ways in which the
statistical methods used to study death
rates may also be used to study rates of
some other particular type of event in a
clinical trial. Analysis of survival dura-
tion in a randomized trial would usually
involve obtaining:
(i) Descriptive graphs of the observed
outcome in each treatment group
(" life tables ") which can be com-
pared with each other visually.
(ii) A P-value to see if the observed
differences between treatment
groups could plausibly be just
chance (using the " logrank test ").
(iii) Information about how survival
28
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differs between groups of patients
who differ with respect to an " ex-
planatory variable ", such as age
or disease stage, recorded at the
time of randomization (using life
tables and logrank tests to compare
these groups with each other).
(iv) Retrospective stratification, based
on the findings in (iii), followed by
recalculation of the P-value com-
paring treatment groups making
proper allowance for which of
these strata each patient is in.
17.-Definition of the " trial time " for each
patient
" Time " is measured for each patient
from that particular patient's date of
randomization.
After deciding to analyse the results
a stopping date, perhaps the end of a
particular month, is chosen and for each
patient in the trial it is determined
whether he was alive or dead on that date
and, if dead, the date on which he died.
(Deaths occurring shortly after the chosen
stopping date are ignored in this analysis,
even if they are known of when analysis
occurs, since otherwise the risk of death
would be slightly exaggerated.) If the
collaborating centres have enough ad-
vance warning of the stopping date, they
can arrange appointments for all their
surviving patients for a few days after
this date, and the data collection can then
be completed within a matter of weeks
of the stopping date. It is certainly not
sufficient to rely on busy collaborating
physicians to notify a trial centre when-
ever deaths occur; delays of several
months would then be commonplace,
and some deaths might be completely
missed. Curiously, recall (in response to
telephone enquiries) of how long ago
deaths occurred or patients were last seen
is very unreliable, many events being
remembered as being considerably more
recent than they actually were. Exact
dates when patients died or were last seen
must, unfortunately, be determined.
For each patient one now knows
whether or not he died and the time for
which he was at risk, which we call his
trial time. This runs from the date of his
randomization to the date of his death or,
if he did not die, to the stopping date.
The trial time of a lost or emigrated
patient runs to the date of loss; if loss may
have occurred because therapy was not
being successful (or because it has been
completely successful), there is no satis-
factory way of allowing for this fact, so
don't let it happen! Note that survival
in a therapeutic trial is measured from
the date of randomization, not the date of
first symptoms, presentation or starting
treatment. Early deaths, occurring be-
fore treatment has even started, are thus
included in the actual treatment com-
parison.
18.-The Life Table
This is a graph or table giving an
estimate of the proportion of a group
of patients that will still be alive at
different times after randomization,
calculated with due allowance for
incomplete follow-up.
If all the patients in a trial have died,
it is easy to calculate the proportion of
patients surviving to the end of a particu-
lar day from randomization, and a graph
of this proportion against time from
randomization would be a simple life
table, for the special case where all have
died.
Unfortunately, this simple and sensible
graph of " proportion alive " against
" time since randomization " can be fully
plotted only if all the patients are already
dead before analysis of the data is under-
taken. For example, if some of the
patients are still alive with trial times
less than one year (because they were
randomized only a few months ago), we
cannot yet know if they will eventually
survive a full year from randomization
or not, and so there is no simple and
obvious estimate of the proportion of all
patients who will be alive at one year.
3
R. PETO, M. C. PIKE ET AL.
However, to survive a whole year, a
patient has to survive each of the 365
days comprising it, and this apparently
trivial observation is the key to efficient
estimation of how many will live the full
year out. We need first to look at the death
rates observed on each individual day,
and then to argue that, for example, the
way to live 31 days is to live 30 days and
then to live one more day.
Translated into the language of
probabilities, this means that the
probability of living 31 days from ran-
domization is the probability of living 30
days multiplied by the chance of surviv-
ing Day 31 after living 30 days: they are
multiplied together since this is how one
combines such probabilities. It is essen-
tial that the previous sentence be clearly
understood, for without it the remainder
of this section will be obscure. (It is just
analogous to the calculation that if 2
coins are tossed in succession, the probabi-
lity of both being heads is one-quarter,
this being the product of the probability
that the first coin is heads, which is one-
half, and the probability, after the first
coin has come down heads, that the
second coin will now do so, which is also
one-half.)
This simple rule is all that underlies
the calculation of " life table " graphs.
It follows fairly straightforwardly from it
that the chance of living a year from
randomization is
C1 X C2 X C3 X C4 X ... X C364 X C365
where:
C0 denotes the chance of surviving at
least one day from randomization
C2 denotes the chance of surviving a
second day after you have survived
one day from randomization
C3 denotes the chance of surviving a
third day after you have survived
2 days from randomization
C4 denotes the chance of surviving a
fourth day after you have survived
3 days from randomization
etc., and:
C365 denotes the chance of surviving
Day 365 after you have survived
364 days from randomization.
Unfortunately, we do not know any
of these individual C's. However, we
could estimate any particular one of them
(C365, for example) by looking to see
what proportion of patients who are at risk
on Day 365 actually survived it. Let us
write this observed survival rate for Day 365
as P365 We could use P365, the observed
survival rate on Day 365 among those
alive after 364 days, as a very crude
estimate of C365, the actual chance of
surviving Day 365 after you have survived
364 days. To calculate P365' we study
all patients with trial times greater than
or equal to 365 days; in other words, all
patients who entered the trial more than
364 days ago (so that we have a chance to
see their fate on Day 365) and who were
still alive 364 days after randomization.
(Patients who entered only a few months
ago tell us nothing about P365.) P365 1s
then simply the proportion of these
patients who survive Day 365. If, as
may well be the case, nobody happened to
die exactly on Day 365, then P365 1.
For every post-randomization day, p can
be defined analogously.*
The " life table " estimate of the true
probability (C0 X C2 X C3 X C4 X C5 X
C6 X C7) of surviving 7 days from
randomization is simply p1 x P2 X p3 X
p4 x p5 x P6 X p7; likewise, the " life
table " estimate of the chance of surviving
a whole year from randomization would
be:
Pi X P2 X P3 X P4 X ... X P364 X P365'
a product of 365 observed survival rates.
* Formally, on Day 76 after randomization, P76, the obsqrvod survival rate, equals (no. with trial time
of at least 76 days who did not die on Day 76)/(no. with trial time of at least 76 days). The observed
survival rate on Day 76 after randomization thus makes no use. whatsoever of data from patients who died
before Day 76, or who were randomizedl less than 76 (lays ago.
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Although each individual observed sur-
vival rate (p) is a very inaccurate estimate
of the corresponding chance of survival,
(C) it is a surprising fact that the product
of a lot of p's (the life table estimate
of the chance of still being alive after a
certain time) is quite an accurate estimate
of the product of the corresponding C's
(the actual chance of still being alive then).
It may be noticed that the life table
estimate of the chance of surviving any
particular number of days from random-
ization is thus the product of the life table
estimate up to the previous day, and the
observed survival rate for the particular
day. The life table estimate is exactly
the same as the simple proportion of
survivors if all the patients die before the
trial is analysed (readers can check this
themselves for the first 6 days, for
example). The " life table " (or " sur-
vival curve ") for a set of data is a graph
or table of this estimate against time from
randomization. (The usage has emerged
that either a table or a graph may be
referred to as a " life table ".)
A life table is the most accurate
description of a set of data on the times to
death of a group ofpatients, and physicians
engaged in such clinical trials should be
familiar with its construction and in-
terpretation. In practice, one doesn't
have to worry about the multitude of
days on which nobody happened to die,
for on these days p = 1 and a life table
may stay constant for a whole run of such
days.
Although the life table is much more
reliable than the individual observed
survival rates of which it is composed,
spurious big jumps or long flat regions
may sometimes occur in a plotted life-
table; this is discussed more fully below.
In an MRC trial in chronic granulo-
cytic leukaemia (MRC, 1968), previously
untreated patients were admitted at
several centres from September 1959 to
December 1964. Analysis was under-
taken with the stopping date of 1 January
1967. Fig. 3 is the life table for the
entire group of 102 patients admitted to
the trial. It is slightly irregular, as are
all life tables based on small numbers of
patients, but its general shape gives the
best information that can be derived from
the collected data about the pattern of
mortality of these patients, although its
fine detail is not really informative.
Fig. 4 gives the separate life tables
for the 2 treatment groups of patients-
those treated by radiotherapy and those
treated with busulphan. Evidently, the
busulphan-treated patients have fared
somewhat better. This shows how treat-
ment differences can be illustrated by
survival curves.
If the vertical 00 survivors " axis
is given on a logarithmic scale, the slope
of the survival curve at any given time
CHRONIC GRANULOCYTIC LEUKAEMIA
02 patients
0 100 200 300 400
TIME FROM FIRST TREATMENT, wks.
FiG. 3. Life table for all patients in the
Medical Research Council's first CGL trial.
The numbers of patients still alive and
under observation at entry and annually
thereafter were: 102, 84, 65, 50, 18, 11, 3.
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100 b * Times of death
x Trial times of survivors
o - Correct life-table
--- Incorrect life-table (see text)
S 60_
_ tM ~40 ______________________________________
I-C 4 still at
-> 20 risk at
1400 days
0 250 500 750 1000 1250
TIME FROM FIRST TREATMENT (days)
FiG. 5.-Life table derived from the hypothetical data used as a worked example in Appendix 3. The
numbers of patients still alive and under observation at entry and every 6 months thereafter were:
25, 14, 11, 10, 8, 7, 7, 7, 4.
estimates the death rate among the
survivors at that time. This is sometimes
useful as it shows how the death rate
among the survivors depends on time from
randomization, but since such data usually
have to be presented to people who are
not really familiar with logarithms, log-
arithmic axes should in general be
avoided when presenting life tables, especi-
ally since they magnify the parts of the
life table which are least accurate at the
expense of the more accurate parts.
Fig. 5 gives the life table for the
hypothetical data which are presented
and analysed as a worked example in
Appendix 3. Here, a common feature
of many real life tables is apparent:
the data are so sparse that there are long
periods (e.g. between Day 250 and Day
600) when nobody happens to have died.
The life table consequently consists of
flat regions separated by " steps ", and
again it must be emphasised that any
conclusion based on the fine detail of
such a graph is likely to be wrong.
Particularly, long flat regions at the
right-hand end of a life table do not imply
that the real risk of death among patients
who are still alive then is negligible, unless
a large number of patients have trial
times well into or beyond the flat region.
In Figs. 3, 4 and 5, the trial times
of all individual patients, whether they
died or not, are marked, so it is a fairly
simple matter when looking at the graphs
to see how many patients were still at
risk at any one time. This is done by
counting the points to the right of this
time, and is especially valuable in life
tables such as Fig. 5 where the data are
sparse. If your trial is so big that it
would be impossible to show a distinct
point for each patient, write at several
different times along the foot of the life
table, the number of patients with trial
times of at least those magnitudes. This
has also been done in the legends to
Figs. 3, 4 and 5, although it would really
have been better if these numbers of
patients remaining " at risk " had actually
been written along the bottom of each
graph.
The reason for wanting to know how
many patients are alive and still being
followed up at a particular time from
randomization is that this information
can be used for a quick (but quite accurate;
see statistical note 6) estimate of how
much your life table at that time might
differ from the value it would have had
in a vastly larger, and hence more
accurate, study. However, these esti-
mates should not usually be used for the
calculation of P-values; for this, the
logrank test, which is described below,
is preferable since it takes into account
the overall structure of the 2 curves
being compared, not just their values at
one time.
(Over periods as long as 5 or 10 years
6
PROLONGED CLINICAL TRIALS. II: AN-ALYSIS
from entry, an appreciable proportion of
a group of old patients would be expected
to die from other causes, and so
adjusted" 5- or 10-vear percentage
survivals are sometimes cited. These
are simply the life-table estimates of the
proportion of the diseased patients still
alive at 5 or 10 vears a-s a percentage of
the proportion that would have been alive
had only the national age- and sex-specific
death rates prevailed.)
19.-The Logrank test
This involves counting the number
of deaths observed in each group, 0,
and comparing it with E, the extent of
exposure to risk of death in that
group; the method of calculating E is
given below.
The basis of the logrank test is so
straightforward that it seems surprising
that it was first suggested only as recently
as 1966 (Mantel, 1966). Breslow (1975)
has recentlv written a unified statistical
review paper on the logrank test and
allied approaches to clinical trial data,
which can be consulted for formal justifi-
cation of its widespread use.
The principle is that if, for example, of
the patients under observation on a parti-
cular day after randomization, two-thirds
are in Treatment Group A and one-third
are in Treatment Group B, then on
average two-thirds of the deaths on that
day should occur among A patients and
only one-third among B patients, unless
A is really a more, or a less, effective
treatment than B. WVe mav define the
extent of exposure to risk of death of A
patients on that dav to be two-thirds
the number of deaths on that day, and
that of B patients to be one-third of the
number of deaths on that dav.*
WVhen considering a particular day
after randomization, a little care is
needed to work out the proportions of
A patients and B patients, since patients
who have died before this day must be
ignored, as must patients randomized so
recently that their fate on this particular
dav is not vet known. (In this respect,
the calculation resembles the calculation
of the life table.) For example, if in a
clinical trial. 100 patients are randomized
to A and 100 to B, then on Day 1, 200
patients are at risk, half in Group A and
half in Group B. If, however, due to
death, loss or recent entrv, only 60 of the
A patients plus 40 of the B patients have
trial times of 365 days or more, then on
Day 365, 100 patients are at risk, with
proportions 0-600 in Group A and 0-400
in Group B. If 2 deaths occurred among
these 100 patients on the 365th day after
randomization, the extent of exposure to
risk of death suffered bv the A patients
on Dav 365 would be 1-200 and that
suffered bv the B patients would be 0-800.
In other words, risks are related to the
proportions remaining, not to the pro-
portions originally randomized. Note,
of course, that no calculations need be
performed for days on which no deaths
occur in either group, since the quantity
which we have chosen to call the extent of
exposure to risk of death will necessarily
be zero on all such days. (This illustrates
that our definition of the extent of expo-
sure to risk on a particular day depends
on what actually happened on that day,
not on what might have happened.)
The actual number of deaths observed
on a certain day among the Treatment A
patients will usuallv not exactly equal the
extent of exposure to risk on that day,
especially as this is likely not to be an
exact whole number. The number of
deaths actually observed among the A
patients may be less than the extent of
exposure of the A patients to risk on some
davs and more on other days. If A and
B are equivalent treatments, however,
then over a long period (comprising many
* The general definition is that the extent of exposure to risk of death among a subgroup of patients on
a particular day is the total number of deaths on that dav in the whole study population, multiplied bv the
proportion of the patients at risk on the particular day who are in the subgroup of interest: see Appendix 3
for a worked example.
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individual days) the total number of
deaths observed in A patients should on
average equal the sum of all the separate
extents of exposure of the A patients to
risk of death on each separate day during
this period.
The logrank* test comparing Treat-
ment A with Treatment B during a
certain period involves:
(i) counting the total number of Group
A deaths observed during that
period, calling this OA;
(ii) counting the total number of Group
B deaths observed during that
period, calling this OB;
(iii) calculating the extents of exposure
of the A patients to risk during
each day of the period, adding
them all up to get the total
extent of exposure to risk of death
suffered by the A patients during
this period, calling this EA;
(iv) deriving similarly the total extent
of exposure to risk of death
suffered by the B patients during
this period, calling this EB;
(v) comparing OA with EA and OB
with EB, to see if there are any
marked discrepancies. Table IV
gives such a comparison for the
data from the whole of the MRC
chronic granulocvtic leukaemia
trial (MRC, 1968).
As an arithmetic check, OA + OB
should equal EA + EB, except for slight
rounding errors. (When calculating the
extents of exposure to risk on individual
days, it suffices to work to 3 decimal
places.) It follows that if OA exceeds
EA, indicating that Group A fared worse
than the average of Groups A and B
together, then OB will be less than EB,
indicating that Group B fared better than
average.
This method generalises instantly to
the comparison of several groups of
patients with each other: for each group,
the extent of exposure to risk of death on
a particular day is still the proportion
on that day who are in that group times
the number of deaths on that day; and
again, the total exposure in one group
over an extended period is the sum of the
separate exposures in that group on the
separate days comprising the period. In
any one period, too, the sum of all the O's
will equal the sum of all the E's. For
example, if we were comparing 4 groups,
A, B, C and D, we would finally check
that: OA + OB + OC + OD equals EA +
EB+ Ec + ED.
Two questions are unanswered: " WA'hat
periods should be examined? " and " What
constitutes a marked discrepancy between
G and E? " The second question is
dealt with in Section 20. The answer to
the first question depends on the disease
being studied; for acute myeloid leukae-
mia, where there are many early deaths
during the first few months after random-
ization, followed by partial stabilization, it
might be sensible to look separately at
what happens in 2 periods, the first includ-
ing all days in the first 6 months after
randomization, and the second comprising
all subsequent davs. Alternatively, for
another disease, one might look separately
at the apparent treatment differences in
3 periods, the first year, the second vear,
TABLE IY.-MRC Chronic Granulocytic Leukaemia Trial
Treatment
group
Busulphan
Radiotherapy
All patients
No. of
patients in
group
48
54
102
0, observed
no. of
deaths
40
50
90
E, extent of
exposure to
risk of death
51 95
38 -05
90-00
Relative
death rate,
O/E
0- 77
1-31
1-00
* The name " logrank " derives from obscure mathematical considerations (Peto and Pike, 1973) which
are not worth understanding; it's just a name. The test is also sometimes called, usually by American
workers who cite Mantel (1966) as the reference for it, the " Mantel-Haenszel test for survivorship data ".
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and all subsequent years. Whatever
periods the time from randomization is
split into, the most important com-
parison is that for all periods together.
This is the "' logrank test" comparing
the overall difference between the whole
survival curve for A and that for B.
Tables (such as Table IV) of observed
numbers of deaths, 0, and extents of
exposure to risk of death, E, for the whole
period of observation, give a concise
summarv of the trial results.* The ratio
O/E for a subgroup is called the relative
death rate for that subgroup, because it
approximates to the ratio of the daily
death rate in that subgroup to the daily
death rate among all groups combined.
Therefore, the ratio of 2 O/E's from
different subgrups can be used to des-
cribe the apparent ratio of the correspond-
ing death rates. For example, in Table
IV, the relative death rates on the 2
treatments are 0-77 and 1-31, suggesting
that the true death rate ratio is about
0-77/1-31 = 0-6: i.e., very crudely, that
busulphan prevents or delays about 40%
of the deaths that would occur with
radiotherapy.
Actually, in one group the death rate
will probably not be constant; it might,
for example, be more rapid among
patients who have only just been ran-
domized than among patients who have
been in the trial for over a vear. If the
death rate in one group is thus not
constant, how can we talk meaningfully
about the ratio of the death rates in 2
groups? If time from randomization is
subdivided into periods which are short
enough for the death rates not to varv
much within one time period, then within
each separate period it is meaningful
to talk about the death rates in 2 sub-
groups of patients, and the ratio of these
2 death rates. Some sort of average of
these death rate ratios in different time
periods could be formed, and this
z average death rate ratio'" is what is
really estimated by the ratio of 2 O/E's
for 2 subgroups of patients.
A statistical test based on the dif-
ferences between O's and E's is optimal,
in the sense that if there really is a
slight difference in the efficacy of the
treatments (whereby the death rate in
one group consistently exceeds that in
the other group by a certain proportion:
see statistical note 5 in Part I) no other
valid statistical method is as likely to
vield a significant difference. We shall
now describe how P-values are calculated
from the differences between O's and
E's to help decide whether such differences
could plausibly have occurred by chance
alone.
20.-Loqrank sinificance levels
P-values may be estimated by com-
paring the sum of (O-E)2/E with an
appropriate chi-square distribution.
The approximate statistical signifi-
cance of differences between observed
numbers of deaths, 0, and extents of
exposure to risk of death, E, in different
groups, can be calculated quite rapidly.
In each group we can calculate
(O-E)2/E. The more discrepant the value
of 0 in a particular group is from the
value of E in that group, the bigger
(0-E)2/E in that group will tend to be.
Suppose that we calculate (0-E)2/E in
each group and that we then add these
up, one term from each group. This is
something which we shall want to discuss
in many places in this paper. It is
therefore convenient to have a brief name
for the sum of all the (0-E)2/E values,
and we choose to call it X2. Likewise,
we shall let the svmbol k denote the
* There is obviously some sort of analog between E, the total extent of exposure in a subgroup, and an
expected nurmber of deaths in that subgroup, and because of this, E is often referred to as the " expected
number of deaths ". Unfortunately, in a group of patients who stay alive longer than average, E may, as
in Table IV, exceed the number of patients originally randomized into a group. Since it would seem
paradoxical to " expect " more deaths than there are patients, the name " extent of exposure " for E is
perhaps preferable. However, both names are now sanctioned by usage in published work and, whichever
name is used, the statistical arguments are equally valid.
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number of groups being compared with
each other: in many clinical trial analvses,
k 2.
If there are k treatment groups and
the prognosis of each group is, in fact,
the same, then X2 will usually be roughly
equal to (k-l).* If, on the other hand,
the prognosis in different groups is really
different, the observed numbers, 0, in
each group will be svstematicallv different
from the corresponding extents of ex-
posure, E, and X2 will tend to be greater
than k-1. Large values for X2, therefore,
although they could arise by chance,
constitute evidence for real differences
between the prognoses in the k groups.
It is possible to calculate the approximate
probability that X2 would, if the prog-
nosis were the same in all k groups,
exceed any particular given value-and,
of course, the larger the given value the
less probable this is.
This probability, which we call the
significance level " or "P-value ", is
estimated by an analogy between the
behaviour of X2 if the k treatments were
identical and the behaviour of one of the
standard distributions of statistics, the
chi-square distribution. Actuallv, there
are lots of different chi-square distribu-
tions, each with a different mean value;
we can have a chi-square distribution
with mean 1, a chi-square distribution
with mean 2, and so on: the mean value
of a particular chi-square distribution is
called the degrees of freedom" of that
chi-square distribution, for reasons which
are not essential here. Since, if the
prognoses are the same in all k groups,
the expected value of X2 is approximatelv
(k-i), we shall use the analogy with the
chi-square distribution with mean (k-i).
This comparison enables us to sav that P,
the significance level, is approximatelv
the probability that an ordinary chi-square
distribution with k-i degrees of freedom
shall equal or exceed the observed value
of X2. Some of these probabilities are
listed in the footnote.t
As an example of the use of these
methods, consider the data of Table IV.
There are 2 groups, so k = 2 and X2, the
sum of (O-E)2/E, is
(-11-95)2/51-95 + (11-95)2/38 05 = 6-50.
(N.B. This sum has onlv one term
for each group, based on the numbers of
deaths: no contributions come from the
numbers of survivors.) Comparison of
this value with the tabulated behaviour
of chi-square with one degree of freedom
shows that the observed difference be-
tween the 2 treatments is more extreme
than would commonly arise bv chance
alone: since 5-02 < 6-50 < 6-63, 0-025 >
P > 0-01 and since 6-50 nearly equals
6-63, P - 0-01. We might, in a publica-
tion, savy The difference is statistically
significant (X2 = 6-a0, d.f. 1, P_
0-01)."
More precise significance levels can be
* Although the reasons for this rough equality wiH not be apparent to most non-statisticians, it must
unfortunatAy be taken on trust, as its proof is beyond the scope of the present paper; the same is true of the
chi-square analogy which follows.
t For any mean value (1, 2, 3, 4 .), the chi-square distribution with that mean has a probability just
under 0-05 of exceeding (mean -3,'mean). For comparisons of 2, 3, 4, 5 or 6 groups with each other,
the minimal value of X2 nec-ssary to generate certain particular P-values is tabulated.
Mean value
of X2
(i.e. degrees
of freedom
of chi-square
analogue)
1
3
4
5
Minimal X2
P< 0-1 P< 0-05 P<0-025
2-71 3-84 5-02
4-61 5-99 7-38'
6-25 7-81 9-35
7-78 9-49 11-14
9-24 11-07 12-83
P < 0-01
6-63
9-21
11-34
13-28
15-09
P < 0-005
7-88
10-60
12-84
14-86
16- 75
P < 0-001
10-83
13-81
16-27
18-47
20-52
No. of
groups of
patients
being
compared
2
3
4
5
6
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calculated for publication purposes (Peto
and Pike, 1973-see statistical note 7 on
p. 38) if statistical assistance is available,
and these will usuallv be slightly more
extreme than the significance levels
derived by this simple chi-squared
analogy. A worked example of the use
of all the methods so far described on
some hvpothetical clinical trial data is
given in Appendix 3, where life tables,
O's and E's and P-values are calculated
from first principles.
21.-Explanatary information (prognostic
factors)
If patients are retrospectively divided
into strata, life tables and logrank
methods can compare the prognosis in
different strata, testing for hetero-
geneity or, if possible, for trend.
Explanatory information is any data
that can help to explain some of the
differences between the survival times of
different individuals. Broadly speaking,
anv facts collected from all the patients
before their entry to a clinical trial can be
used in this way without difficultv. In-
complete information is of much less use,
and it may not be possible to deal with it
in an unbiased wav. Information col-
lected once treatment is under way may be
valuable, if it is collected from all the
survivors at a particular time after their
first treatment. This is, however, usually
more difficult to arrange than is antici-
pated when the trial is designed, so data
collected at the time of original randomiza-
tion is usually of the greatest value.
With several items of explanatory
information available from each patient,
it is possible to determine (using life
tables and the logrank test, but testing
between groups defined by the explanatory
variables instead- of between different
treatment groups) which (if any) of these
items are correlated with prognosis. It
is also possible to test whether an apparent
influence on prognosis is merely due to an
association with another, possibly more
important, factor (Cox, 1972; Breslow,
1975). There is a worked example of
this in Appendix 3.
For example, in analysing the MERC
mvelomatosis trial (MRC, 1971a), there
was no apparent difference between the 2
treatment schedules tested, and interest
turned to these explanatorv variables.
Table V gives the observed numbers of
deaths, and the extents of exposure to
risk of death in this trial, according to
the blood urea of the patients at presenta-
tion. It can be seen from the column
of values of O/E that the lower the initial
blood urea, the better the prognosis.
We could, of course, check how
easily heterogeneity as extreme as, or
more extreme than, that actuallv seen
between the O's and E's in Table V
could arise simply bv chance, by calcu-
lating:
X2 (79 - 122-06)2 ± (81 - 74.60)2
1 _1__.A9 t 7XA 2Lzz UU 14-OU
(53 - 16.34)2
16 34
In this case X2 - 97.99 and, since there
are 3 groups, it is appropriate to compare
X2 with tables of chi-square on 2 degrees
of freedom. The previous footnote shows
that the probability of chi-square with 2
degrees of freedom exceeding 13 81 is
0-001. The probability is therefore much,
much less than 0-001 that X2 should
attain a value as large as or larger than
97-99 bv chance alone. In publishing
such data, we might therefore write
X2 = 97.99, d.f. = 2, P < 0 001" (or
even, for emphasis, P <6 0-001).
This value of X2 is so extreme that it
answers the question of chance beyond
doubt. However, in less extreme cases,
it is preferable to make use of the fact
that the groups are ordered, and to test
for the existence of a trend in prognosis
as we go from the first group to the last
group. The trend test seeks not just
heterogeneity, but plausible heterogeneity,
in which the middle group (or groups)
tends to have a more average prognosis
than the outer groups, and the outer
11I
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TABLE V.-First MRC Myelomatosis Trial
Initial urea No. of 0, observed E, extent of Relative
(mg/100 ml patients in no. of exposure to death rate,
blood) group (leaths risk of death O/E
0-39 113 79 122-06 0-65
40-79 92 81 74-60 1.09
80+ 53 53 16-34 3-24
All patients 258 213 213-00 1-00
groups tend to differ in opposite directions
from the average prognosis. Whenever
more than 2 groups are being compared,
and they do have a natural ordering, it is
likely to be more sensitive to test for
trend than to test for heterogeneity.
Technical details of how to test for trend
are relegated to Appendix 5.
However, when a plausible contrast
is as marked as that in Table V (the
relative death rate in the high-urea
group being about 5 times as big as that
in the low-urea group), no sane reader
will suppose that the differences between
the O's and E's arose simply by chance.
This particular P-value, therefore, answers
an irrelevant question, and need hardly
be cited; the most important thing with
such data is to characterize the difference,
not to test whether it could be due to
chance or not. To describe the de-
pendence of prognosis on initial blood
urea, we might calculate separately:
(i) the life table for the low-urea
patients,
(ii) that for the medium-urea patients,
(iii) that for the high-urea patients,
and plot all three of them on a single
graph of " estimated % alive " versus
" time since entry to study ".
22.-Use of prognostic factors to refine
the treatment comparison
If a treatment difference among
patients in one stratum is calculated,
the sum of all such differences, one
per stratum, yields an overall test
of whether treatment matters among
otherwise similar patients.
In clinical trial analysis, we are
interested in whether apparent differences
between treatments might be due merely
to random allocation of more of the
good-prognosis patients to one treatment
than to the other treatment. Obviously,
anything we know about the major
determinants of prognosis can help us to
answer this question correctly, and help
us to see whether, given the different
numbers on each treatment in various
prognostic categories, there is any residual
relationship of treatment with survival.
In earlier reports of clinical trials,
the first step in the analysis was often to
examine the percentage of each favourable
and unfavourable prognostic feature in
each treatment group and, hopefully, to de-
monstrate that they were not too different.
To ensure this, a policy of initial stratifica-
tion was sometimes adopted, giving
alternate patients in each particular
prognostic stratum alternate treatments.
With modern methods of analysis of
survival data, it does not matter if there
is some imbalance of prognostic features
between treatments, and stratification on
entry is usually unnecessary. The
principle underlying these methods is
very simple: when the trial is being
analysed, find out which of the factors
recorded at entry are relevant to prog-
nosis (by the method of the previous
section). In the light of this analysis,
define a few "prognostic strata ", so
that within each stratum the patients all,
as far as could have been told at entry to
the trial, had a fairly similar prognosis.
This is straightforward, if only one of
your explanatory variables is strongly
related to prognosis. If there is a natural
way of subdividing that one important
variable (e.g. male/female, or Stage I/
Stage II/Stage III/Stage IV), then use
12
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these natural subdivisions to define your
strata. If it is a continuous variable,
for example haemoglobin, you might first
try subdividing it fairly finely (e.g. into
6 to 10 subgroups) and calculate the
observed numbers of deaths, 0, and the
extents of exposure to risk of death, E,
in each such subgroup. Finally, calculate
O/E in each subgroup and pool adjacent
subgroups with roughly similar values of
O/E, to give yourself a few larger strata.
If you have only two important
explanatory variables to allow for, then
first use this approach to each one
separately, splitting each into as few
categories as possible. If you can manage
to split the patients into only 2 or 3
categories with respect to each of the 2
important variables, then your strata
might well be the 4, 6 or 9 different
combinations of categories of these 2
variables. Stratification with respect to
as many as 3 variables is often not
necessary, and stratification with respect
to more than 3 variables is usually both
unnecessary and unwise, unless you have
thousands of patients in your study.
Let us suppose that you have now
defined, on the basis of explanatory
information recorded at entry into the
trial, a few retrospective strata. Within
the first of these prognostic strata calcu-
late, as above, the observed numbers of
deaths and the extents of exposure to
risk of death on each treatment, entirely
ignoring all the patients in all the other
strata. Within the first stratum, the
sum of the observed numbers on the
various treatments will necessarily equal
the sum of the various extents of ex-
posure. If all the treatments being
compared are equivalent, then for any one
treatment group in this first stratum,
the observed number and extent of
exposure will differ from each other onlv
by random fluctuation. If one treatment
is better than the other(s), however, then
for that treatment in this stratum, the
observed number of deaths is likely to be
less than the extent of exposure, although
since we have only looked at a fraction
of all the patients in the trial so far, this
difference is unlikely to be significant.
However, we next repeat this analysis
for the patients in the second prognostic
stratum, and then for the third prognostic
stratum, and so on. For a particular
treatment, we now have an observed
number and an extent of exposure in
every stratum, which differ from each
other only randomly, unless treatment
matters. These may be added, to obtain
a grand observed number, 0, and a grand
extent of exposure, E, for that treatment.
Even if there is no very significant treat-
ment effect within any single stratum,
differences in the same direction in several
strata can reinforce each other so that the
grand O's and E's in certain treatment
groups eventually differ from each other
significantly, if some treatments really are
better than others.
Comparison of these grand observed
numbers and extents of exposure (by
calculating X2, as previously, and com-
paring it with the standard chi-square
distribution with mean one less than the
number of treatments) is not biased in
any way by chance correlations between
particular prognostic strata and treat-
ment, and statistical tests for significant
differences between the grand O's and E's
are therefore the best way to assess real
treatment benefits. In the MRC myeloma
trial, inspection of Table V led us to
define 3 prognostic strata (low, medium,
and high urea) and after this stratification
we eventually found that there was no
significant effect of treatment among
patients with any given level of urea.
Similar techniques can also, of course,
be used to examine the relevance of one
factor to prognosis, with other factors
being constant. A computer programme
capable of doing all such analyses and of
plotting or printing life-tables is available
on request (see p. 20), and a worked
example of the use of explanatory infor-
mation is given in Appendix 3. An
instructive and interesting example of
the use of these methods on real data is
provided by the report of the Medical
13
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Research Council's fourth and fifth thera-
peutic trials in acute myeloid leukaemia
(MRC, 1974).
In multi-centre trials, the differences
between the prognoses of patients entered
at different centres can be substantial.
To allow for this is simple: stratify with
respect to centre, and within each centre
calculate observed numbers of deaths
and extents of exposure to risk of death
as described above with respect to treat-
ment (or some explanatory variable).
Finally, add up all the observed numbers,
and all the extents of exposure for one
treatment (or explanatory variable cate-
gory), obtaining a grand 0 and E for that
treatment (or category). X2, calculated
from the grand O's and E's for all treat-
ment groups, provides a valid test of
whether any real differences between
treatments exist. This is unbiased
whether or not there is marked hetero-
geneity in the types of patients admitted
or in the general standards of medical
management at different centres.
One advantage of dividing the patients
into retrospective strata is that if one
treatment is better than the other, it is
sometimes much more so among certain
types of patients than among others. A
trial where this might be the case is
described in the Example of Section 31,
where methotrexate appears to be of sub-
stantial benefit in acute lymphoblastic
leukaemia remissions only if the white
blood count is low. However, it is
extremely important not to be misled
into seeing effects like this (which are
called " interactions ") in every set of data
analysed. If patients are divided into 3
or more strata, then since each stratum
is smaller than the whole study, purely
random differences between treatments
will be more marked in each stratum.
These differences may well point in
opposite directions in different strata,
giving the impression of an interaction,
whether one is really there or not. The
fundamental P-value to be reported is the
overall comparison of treatments, adjusted
by retrospective stratification. If this is
not significant, it is unwise to conclude
without expert statistical assistance that
any treatment differences in individual
strata are real.
A fuller discussion of statistical
methods for the identification and use of
prognostic factors may be found in
Armitage and Gehan (1974).
23. Bad methods of analysis
A list is given of some common
methods of analysis of survival data
which are either inefficient, mislead-
ing or actually wrong.
(1) The comparison of life tables at
one point in time, ignoring their structure
elsewhere, is in general inefficient (except
for diseases which are very rapidly fatal
or cured). Moreover, if the point at
which the comparison is being made is
chosen (e.g. Mathe et al., 1969) because
the difference there is substantial, the
comparison is invalid unless special
statistical methods are used, and these are
inefficient.
(2) If few patients are at risk for
more than a certain time, and after that
time none of these few happens to die,
there will be an apparent " plateau " in
the life table. Such plateaux at the ends
of life tables are very common, and
should never be taken as evidence that
" after a certain time most patients are
cured" unless there are large numbers of
patients still at risk at the time of the
plateau. (Likewise, a sudden and
meaningless big drop can sometimes
occur near the right-hand end of a life
table.)
(3) " Median* survival times" are
* Definition: If half the patients will (lie within a certain time from their randomization and half willlive longer than that, time, that time is the " Mediani survival time " for these patients. It can be estimated
by calculating the life table for these patients and seeing on which (lay the life table (which estimates proba-bility of survivinig) crosses 500o If t,he life table has long flat regions near 50% then this estimate(d median
will be very imprecise. For example, in Fig. 5 the median suggested by the graph is at 210 (ays but if
2 of the early deaths had been avoided the mediain would have been at 630 days!
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very unreliable unless the death rate
around the time of the median survival is
still high. Even in quite extensive
data, median survival times can be very
inaccurate. Although median survival
times are widely cited, they should there-
fore be treated with great caution, except
for diseases in which nearly everyone
dies, the data are extensive, and the life
table falls rapidly through the whole
region between 7000 and 3000 alive
(the region in which the life table is
used to estimate the median). Average
survival times can be far worse, and
should almost never be cited.
(4) A simple count of the numbers
dead in each group is inefficient (except
for diseases which are rapidly fatal or
cured), as it wastes the information as to
exactly when each death occurred.
(5) The best estimate of the proba-
bility of living 4 years, say, from
randomization, is given by the value of
the life table at 4 years. This is because
the life table makes proper use of partial
data, from patients who have been studied
for only part of the first 4 years of their
disease. Estimates other than the life
table should never be constructed without
expert statistical guidance. A less
accurate but valid estimate is given by
the proportion of the people who were
randomized 4 years or more before the
stopping date, who were still alive 4
years after their randomization. The
number of deaths by a certain time
divided by the total number originally
randomized (e.g. Mathe et al., 1969)
systematically underestimates the risk of
death if some patients only entered
recently, since the recent patients have
not yet had their full chance of dying.
Conversely, the number of dead before
year 4 divided by the number dead
before year 4 plus the number surviving
at year 4 (a common error) systematically
overestimates the risk of death by year 4,
since recent patients could not count
among the living but inflate the number
dead.
(6) Study of survival from first treat-
2
ment rather than from randomization is
undesirable, especially if the treatments
being compared are such that the delays
in initiating them in ill patients might
differ. Study of survival among those
who have lived long enough for a certain
number of courses of treatment to have
been given may misleadingly exaggerate
the chances of survival. These are not
absolute statistical prohibitions, of course,just warnings!
(7) The connection of the bottoms of
the steps of life tables, such as that in
Fig. 5 by sloping lines is improper,
as it results in a graph which is a biased
estimator of the proportion surviving at a
given time. (Connection of the tops
of the steps with each other would be
oppositely biased.)
(8) Other significance tests could be
used instead of the logrank test-for
example, Gehan's (1965) modification of
the Wilcoxon rank sum test is used in
many American studies, and it is certainly
a valid method to use. The advantage
of the logrank test is that if there really
is a slight difference between the groups
being compared, whereby the death rate
in one group consistently exceeds that in
the other group by a given proportion,
then this difference is more likely to be
detected by the logrank than by any other
valid assumption-free test (see statistical
note 5 in Part I of this report).
(9) Believing that a treatment effect
exists in one stratum of patients, even
though no overall significant treatment
effect exists, is a common error. Belief
that a treatment difference exists should
chiefly be based on the overall sum of all
the within-stratum treatment comparisons.
If this is clearly significant, serious
consideration may then be directed to
discovering whether the difference between
the two treatments is more marked in
some strata than in others. (This would
be described by a statistician as an
" interaction " between treatment and
certain strata; the statistical use of this
word resembles the medical use of the
word " synergism".) However, marked
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heterogeneity of the treatment comparison
in different strata can arise by chance
more easily than would intuitively be
expected, and statistical assistance should
usually be sought before accepting any
apparent interactions between treatment
differences and patient characteristi4s as
real.
(10) Failure to check really carefully
that, on your selected stopping date, all
the patients you think are alive really are
alive is unwise; many trial organizers
underestimate the time it takes for news
of death to reach them.
(11) A " one-sided " or " one-tailed"
P-value may be cited in a clinical trial
report; if so, you should usually double it
to get the sort of ordinary P-value which
you are used to, and which would emerge
from the methods given in this paper.
If, in a trial, Group A fares better than
Group B, then the probability of A doing
at least this much better than B just by
chance is the one-sided P-value, while the
probability of the difference between A
and B being at least this big in one
direction or the other (A better or B better)just by chance is the ordinary P-value.
(For emphasis, the ordinary P-value is
occasionally referred to as the two-sided
or two-tailed P-value.)
(12) Published P-values are sometimes
calculated after excluding protocol
deviants, or any other category of with-
drawn patients; if so, they should be
mistrusted. Section 13 in Part I
discussed how and why a reliable analysis
should be done in such trials. It is,
however, sometimes useful not only to do
a rigorous analysis, treating withdrawals
etc. properly, but also to do various
informal analyses omitting certain such
patients, assuming certain of them to
have died soon after loss (or to have lived
for ever), and so on. If all these informal
analyses agree with the rigorous analysis
in some conclusion, it will make that con-
clusion more acceptable to many readers.
(No disagreement can arise if, due to good
trial design, there are few, or no, exclusions
or withdrawals.) If the analyses do not
all agree, the investigator should make
sure he understands why they do not, but
should usually trust the rigorous analysis
more than the others.
(13) In Part I, we argued against the
use of historical controls when random-
ized controls could be used instead.
Although we asserted that most claims
based on historically controlled studies
remain open to reasonable doubt, it should
not be inferred that all historically con-
trolled studies are the same. Certain
investigators appear to feel that any
comparison can be made moderately
respectable simply by labelling one group
of patients " historical controls ", and so,
when reading reports of historically con-
trolled comparisons, one should always
be aware of the possibility of gross errors
of method. On the other hand, excellent
investigators sometimes have to make
cautious use of what are, effectively,
historical controls, especially when the
alternative would be no answer for months,
for years, or for ever.
24.-How much data should be collected
from each patient?
The general principle is: collect as
much data as possible at first presen-
tation, only data which are strictly
necessary thereafter, and analyse the
data you do collect very thoroughly.
Although not essential, the collection
of extensive data on each patient at the
time of randomization (including perhaps
a serum sample, some biopsy material or
some other biological matter*) which can
be stored indefinitely in case analysis of it
is required, can help check to what extent
* Stored samples from a large series of diseased patients can often be of great value when new hypotheses
are devised in the future, especially since analytical results can then be immediately correlated with survivalduration. Any measurement which is strongly correlated with survival for a reason which is not obviousis likely to have such a deep connection with the fundamental disease processes that elucidation of thisis likely to prove really fruitful. This is much less likely to be true of a measurement which, although
abnormal in diseased patients, is not strongly correlated with prognosis.
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any treatment effects that do appear are
due to the chance inclusion of an excess
of good-prognosis patients on one protocol:
in other words, such data can help our
statistical analysis of the treatment effects
to compare like with like. Such data
may also enable us to identify particular
subgroups in which one treatment is
preferable, and anyway, the relationship
of presenting features to each other or to
prognosis in a uniformly treated series can
sometimes be of more interest than the
treatment comparison itself.
By contrast, apart from recording any
significant side-effects of treatment, and
recording the date and cause of death,
plus perhaps the dates of a few other
relevant events, data collected after
randomization are of less value, and
simplicity in what the participating
physicians are asked to record during the
follow-up of each patient should be
sacrificed only for a very good reason.
Most routine data recorded during
follow-up in many clinical trials are never
used in any publication, and were col-
lected partly because the trial designers
had not thought out clearly what they
would really need and what they would
not. It is not easy to know in advance
what will be needed, but the blunderbuss
approach of demanding masses of details
in case one or two items are eventually
needed is wasteful, or worse. Excessive
form-filling can be positively harmful,
if it wastes so much time at the hospitals
that gaps get left in some essential data,
or if doctors become reluctant to enter
patients into this, or some future trial,
because of the administrative burden
anticipated. It should be emphasized
that, although extensive data will need
to be recorded in the hospital notes of
each patient during the follow-up, little
of this need be sent to the trial organizer.
Although the trial organizer need not try
to understand the full clinical course of
each patient, he must however know when
whatever critical events (toxic manifes-
tations, perhaps, relapse and death) he is
interested in occur, and preferably he
should know what circumstances immedi-
ately preceded or accompanied those
events.
If the treatment should, if it is being
effective, cause some observable effect,
like leukaemia remission or solid tumour
shrinkage, on the disease itself then an
assessment of these effects should be made
in each patient. Even if survival is not
significantly different, there may be a
highly significant immediate effect of one
treatment which is of great interest.
Special studies of the progress of the
disease can be added to the clinical trial
at certain centres that wish to do so, and
these may illuminate either the natural
history of the disease or the mechanisms
underlying certain treatment effects.
However, in a multi-centre trial it may
be wise to leave these extra data-recording
tasks as optional activities which any
participating centre can be free from, if it
so wishes, without censure. In trials
where the organizer feels he has to ask
for some follow-up data, he should, soon
after the trial has got properly under way,
reconsider what data to request (or how
emphatically to demand it) in the light of
which requested items actually get very
incompletely documented, how much work
each item actually involves, and any other
practical considerations that have arisen.
If some changes are necessary or some
work is unnecessary, the sooner this is
recognized the better.
The causes (or circumstances) of death
should definitely be recorded, if possible,
and grouped into a few distinct categories.
For instance, in myelomatosis we might
try to separate deaths according to
whether the patient died of:
(1) " myeloma kidney " during Year 1
(2) other causes during Year 1
(3) sudden onset of drug resistance
after Year 1
(4) other, after Year 1.
It is obvious that the determinants of
myeloma kidney and drug resistance
may be completely independent of each
other and that separate analyses of these
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4 separate categories of death could be
enlightening. Other subdivisions of
mortality (e.g. whether neutropenia pre-
ceded death) could be useful for other
purposes.
Two separate, but extremely im-
portant, ways in which retrospective
enquiry about the events preceding each
death may be of value are (i) that such
enquiry may suggest new therapeutic
strategies designed to prevent particular
causes of death; and (ii) that such
enquiry may strongly suggest that some
preventable side-effect of one treatment
is causing a few particular deaths, even
though the number thus caused is far too
small to be noticed in any comparison of
overall mortality.
For example, in 1964, melphalan
was only available in 2 mg tablets, the
daily dose was difficult to adjust, and it
was discovered that a few deaths of
melphalan-treated patients were preceded
by drug-induced neutropenia. Warnings,
and the manufacture of 0 25 mg tablets,
coincided with the cessation of such
deaths. Likewise, in acute lymphoblastic
leukaemia 10 years later, some deaths
were found to be preceded by neutropenia.
Review of the case histories of those who
died showed recent radiotherapy in almost
every case, and further studies then
discovered that drugs and radiotherapy
given in the particular time relationship
which had unfortunately been used,
caused far more neutropenia than their
separate actions would suggest. Finally,
the small and non-significant excess of
early deaths in acute myeloid leukaemia
patients treated with asparaginase was
confidently attributed to the asparaginase,
because only among asparaginase-treated
patients had marked granulocyte de-
pression apparently contributed to death.
25.-Subdividing the follow-up period
Mortality may have different corre-
lates during different phases of the
natural history of the disease, and
these should be sought separately.
Splitting the time after follow-up
into about 3 different periods, and com-
paring the logrank 0 with E in each
period separately, as well as in all 3 added
together, is a useful safeguard against
misinterpreting situations such as those
illustrated in Fig. 6, where one treatment
is only better than another in certain
periods. Fig. 6(i) is an ordinary situation,
where A would be better than B in each
100(i)
0
1 2 3
years
100
(ii)
Q)
0
1 2 3
years
100(iii)
a)
0
1 2 3
years
FIG. 6. Three hypothetical ways in which
treatments might cliffer in their effects on
survival: for each, % alive is plotted against
number of years since randomization
separately for treatments A and B.
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year. Fig. 6(ii) is a situation where A
would be better than B in the first and
second years, with no treatment com-
parison possible in the third year, since
there are almost no B survivors to com-
pare with the A survivors. Fig. 6(iii)
depicts a situation which is often worried
about, and occasionally encountered,
where the treatment which is initially
better is actually worse in the long run.
The logrank test for data such as those in
Fig. 6(iii) would show that the death-
rate among A survivors was better in
the first year, worse in the second year,
and worse in the third year. In Figs. 6(i)
and (ii) the overall logrank test would
necessarily show A to be better than B
overall, but in Fig. 6(iii) any result could
emerge from the overall logrank test
(A better overall, B better overall, or no
difference overall).
Suppose that an intensive treatment,
which might well kill a substantial num-
ber of patients early in the trial, is to be
compared with a gentler treatment, which
is probably not as fatal in the short run
but which may be less curative in the
long run, producing the pattern illustrated
in Fig. 6(iii). Here, it would be sensible
to subdivide time from randomization
into an initial period (during which most
of the deaths from the intensive treat-
ment would be expected), and a later
period, and to accumulate (O-E) for each
treatment in the initial period only and
(O-E) for each treatment in the later
period only, examining these separately.
The split between " early " and " late "
should be chosen either soon after
the intensive treatment becomes less
intense, or from consideration of the
overall survival curve for all patients
together to find when the overall death
rate changes. The split should not, of
course, be chosen after examination of the
2 separate survival curves for the 2 treat-
ments, for it is too easy to find a time
when one treatment has a temporary
advantage over the other. Subdividing
time in this way is also good policy when
the nature of the disease changes as time
goes by, e.g. from initial crisis to remission
maintenance, as the determinants or
correlates of mortality in one period may
differ from those in the other. Again,
the overall survival curve could be used
as an unbiased guide on where to split
time to separate an early period of rapid
death from a later period.
26.-Arranging the manner in which data
will be collected
A controlled clinical trial is a sub-
stantial research undertaking, and
sufficient time and money must be
set aside to ensure that the records are
always complete and up-to-date.
(1) Make sure that the (extensive)
initial data from each patient are collected
centrally and checked for completeness
immediately the patient is entered, so
that missing, obscure or unreadable items
can be corrected quickly. Retrospective
efforts to supply missing data or check
implausible items can be very difficult,
and can seriously delay the analysis of the
trial. If some data are missing, however,
it is (unfortunately!) worth making con-
siderable efforts to collect them, if there is
any possibility of doing so, as missing
data make the statistical analysis much
more difficult, and may make the trial
report less easy for other workers to inter-
pret without serious doubts about certain
of its conclusions.
(2) If something is assessed by a
number, record that number exactly,
even though the margin of error may be
very wide, and not some rounded or
grouped version of it. (E.g. it is better
to record haemoglobin exactly than to
use it to categorize patients as anaemic/
not anaemic, and it is better to record
cigarette consumption exactly than to
divide patients into ranges such as 1-4,
5-14, 15-25, etc.) It is easier to devise
appropriate groupings of numerical data
when analysing than when designing the
trial. Record dates of birth exactly (not
just age), as this is sometimes very useful
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for tracing lost patients, especially if use
may be made of official government
records. *
(3) By contrast, if something can be
assessed only subjectively (e.g. general
condition of patient, nature of tumour,
previous history, reasons for presentation,
etc.), it is usually worth forcing, albeit
slightly artificially, the physician recording
the data to do so in certain pre-specified
categories (e.g. good, fair, bad; well-
differentiated, intermediate, un-
differentiated). Although categorization is
not helpful when describing an individual
case history to a colleague, it is essential
for describing a group of case histories,
and categorization will either be done
with some loss of precision by the
physician examining the patient, or it
will be done later with a greater loss of
precision by somebody examining the
medical records of that patient.
For example, the Eastern Co-operative
Oncology Group simply record " perfor-
mance status ' as 0-4, where 0 normal
activity, 1 symptoms but ambulatory,
2 in bed less than half the time,
3 in bed more than half the time, and
4 completely bedridden. Zelen finds
that if advanced cancer patients are
divided with respect to performance
status, the median survival times are very
different. Although this may not be a
very useful finding biologically, it does
mean that if this simple question is asked
of all patients on entry to a therapeutic
trial in advanced cancer, the treatment
comparison in that trial will be more
accurate. (By retrospective stratifi-
cation based on this information, we can
get closer to the ideal of comparing like
with like.) An alternative performance
scale is described in Zelen (1973), where
among about 1000 patients with inoper-
able lung cancer " performance status "
was more important than histological
type, disease extension or any of the usual
information!
Usually, categories containing very
few patients are not useful, and have to
be merged with other categories, so do
not create such categories unless there are
strong medical reasons for doing so.
(4) If, in a clinical trial of over 100
patients, you choose to record a lot of
presenting features, it is probably worth
obtaining programming assistance and
getting a convenient computer program
set up before starting the statistical
analysis, so that any particular tabulation
of presenting features against each other
or against prognosis can be obtained
easily. Otherwise, the data will not
receive the attention which, in view of the
cost of such trials (Pike, 1973), they
deserve. The " SPSS " system, which is
available on most large computers, is of
some value, but unfortunately it does not
implement the logrank test. A FOR-
TRAN program is available which is
easy to use and capable of calculating
and displaying life tables, performing
logrank tests, devising strata, and analys-
ing the effects of one factor (e.g. treatment)
making full allowance for some others
(e.g. the important explanatory variables).
Copies of this will be supplied on request,j
at a slight charge to cover duplication and
postage.
(5) If the data may eventually be
* In the UK, a clinical trial organizer may writ3 to the Registrar-General, Department of Medical
Statistics, Office of Population Censuses and Surveys, St Catherine's House, 10 Kingsway, London W.C.2,
giving his credentials as a bona fide research worker plus a very brief outline of the trial, asking the R-G for
help in monitoring the dates of death of all trial patients who are normally resident in the UK. If the R-G
agrees, and is later supplied with the full name and exact date of birth of each trial patient (either in one
batch, after intake has ended, or in a few batches as it progresses), together with a fee of nearly £1 per
patient, then the R-G will notify the trial organizer whenever any deaths occur, giving the date and certified
cause of death, and the name of the physician who certified the death. (The trial organizer will be notified
immediately if any of his batch of patients are already dead.) Adequate follow-up of survival is thus much
easier in Britain than elsewhere, for the R-G will usually agree to help any reasonable project by bone fide
medical research workers, especially if recent addresses or NHS ntumbers can also be supplied by the trial
organizer for most patients.
t P. G. Smith, DHSS Cancer Unit, 9 Keble Road, Oxford, England.
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transferred onto a computer, they should
be recorded in such a way that they can
be transferred with a minimum of trouble.
Notes on how to do this constitute
Appendix 4.
27.-Assessment by separate causes of death
Life tables and logrank tests may
easily be used to study separately
different causes of death.
If the effect of a presenting feature
on the difference between 2 treatments is
likely only to affect one (or a few) causes
of death, we may choose to look separately
at those causes of death which are
considered relevant. The previous
methods of analysis carry over exactly to
this situation, the numbers at risk on
each day being just as before, although
the extent of exposure to risk of death
from a relevant cause on a particular day
is related, not to the total number of
deaths on that day, but to the total
number of relevant deaths on that day.
Likewise, in calculating the life table, we
calculate for each day the proportion who
do not die of one of the relevant causes,
and then combine these proportions, as in
Section 18, to obtain the life table
description of mortality from relevant
causes only. (This is equivalent to treat-
ing deaths from other causes as if they
were losses to follow-up, assuming that
the different causes of death being studied
are independent. Unfortunately, this
assumption cannot be tested statistically,
but must instead be judged reasonable or
not on biological grounds.) For example,
in the current MRC polycythaemia trial,
which may last for 10 years, we may
exclude from certain analyses deaths
from causes that are unlikely to be
related to polycythaemia or its treatment.
Actually, we shall calculate separately
the observed numbers of relevant deaths
and the extents of exposure to risk of
relevant death by treatment group, and
the observed number of non-relevant
deaths and the extents of exposure to
risk of non-relevant death in each treat-
ment group, so that readers can look
either at relevant mortality or at total
mortality: observed numbers of deaths
from relevant and non-relevant causes can
be simply added together to give total
numbers of deaths, and so can extents of
exposure to risk of relevant and non-
relevant death. Separating a few major
causes of death, and calculating in each
treatment group the observed numbers of
deaths from each cause, and extent of
exposure to risk of death from each
cause, can help the interpretation of data
from clinical trials of slowly progressive
diseases. Again taking an example from
the polycythaemia trial, we may also
examine separately (a) the deaths due to
onset of acute leukaemia, (b) the deaths
due to marrow fibrosis, and (c) other
deaths, to see whether active cytotoxic
treatment is more leukaemogenic than
simple venesection.
28.-Other end points
Life tables and logrank methods can
find whether, among survivors on a
given day, any particular endpoint is
more likely in one group than another;
this is very useful, but can be misused.
It may be of use to note that these
methods of analysis can as easily be
applied to the influence of treatment on
events other than death: time to first
detection of leukaemia in the central
nervous system; time to first cardio-
vascular event (fatal or not) and so on.
In many clinical trials studying solid
tumours, 2 separate analyses, one of time
to local recurrence and one of time to
metastatic spread, may be required in
addition to a full analysis of survival
duration.
Exactly analogous statistical tech-
niques may be used for any such analyses,
except that now we are interested in the
time from randomization to the first such
" event" instead of to death. Con-
sequently, patients contribute no further
information to such an analysis once their
first " event " has occurred. The only
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difficulty is to decide how to deal with
patients who die without suffering the
event of interest.
If the event is such (e.g. neoplastic
recurrence) that few patients die without
previously suffering it, the most satis-
factory course, for reasons which will soon
become clear, is undoubtedly to define
our interest as being in " recurrence or
death not preceded by recurrence".
This means that our life tables will
estimate the proportions of recurrence-
free survivors at different times, and our
O's and E's will test which treatment
best prolongs disea8e-free survival.
If, however, the event is such that
more patients die without suffering it
than ever suffer it, study of it might be
swamped if we mixed in all the patients
who died without it. An example of this
will arise in the current MRC trial com-
paring venesection with venesection plus
cytotoxic treatment for polycythaemia:
whether or not any significant difference
in total mortality emerges, we shall want
to know if, compared with simple vene-
section, the cytotoxic treatment is
leukaemogenic. Counting the few
patients who develop leukaemia (including
leukaemias which are fatal before the
analysis is undertaken and leukaemias
which are not) in each group is easy.
Calculating the extent of exposure to risk
of leukaemia is also easy: we simply
argue that on a given day after randomiza-
tion, all patients who are still alive and
free of leukaemia would, if cytotoxic
treatment were not leukaemogenic, be
equally likely to develop leukaemia. The
only difference from our original analysis
arises when counting the numbers of
patients still alive and at risk on a
particular day after randomization (in
order to calculate the proportion of them
that are in a particular grouip). Now, we
must omit not only, as before, those
patients who entered too recently for us
yet to know their fate on this day after
randomization, but also those who have
already developed a leukaemia before this
day. This is easy: for purposes of the
statistical analysis of leukaemia incidence,
re-define the trial time, for patients who
eventually get leukaemia, as the time
from randomization to leukaemia
diagnosis. (For patients who did not get
leukaemia, the trial time runs as before to
death or, if not dead, to the stopping
date or date of loss.) Now the extent of
exposure to risk of leukaemia in Group A
on a particular day after randomization
is the total number of patients in the
whole study who get leukaemia on that
day, multiplied by the proportion of
patients with trial times at least that long
who are in Group A.
Once the underlying principle of asking
"Among the event-free survivors on a
particular day after randomization, are
people in each group equally likely to
suffer an event on this day? " is mastered,
its applications can be very varied and
very useful: the method automatically
makes perfect adjustment for the effects
of differences in mean duration of risk in
each group (and for the effects of differ-
ences in risk at different times after
randomization) on the expected number
of events in each group.*
Another example of the use of these
methods to search for a particular end-
point, was the proposed MRC trial of oral
hypoglycaemic agents in diabetes, where
the main question of interest would have
* There is, however, one possible source of error which may arise if some patients (lie without being
observed to have suffered the unwanted " event ". Those who (lie are never a random sample of those who
remain, usually because their disease state was more severe, but sometimes (causing severe bias) because
causes which would have culminated in the untoward event whose incidence we wish to study actually
led to death, just before the relevant event was observed. In either case, (lelay of (leath by ani effective
treatment may jtust allow the relevant event to be observed and counted against that treatment! Use of
the logrank test on such events would correctly indicate that, among the survivors on a given (lay after
randomization, patients given a more effective treatment would be more likely to be observed to suffer such
events, although this would be a very misleading fact.
For example, if leukaemic proliferation in the blood causes conitamination of the central nervouis system
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been their effect on vascular disease.
WVe would have counted the observed
numbers of people in each group who
suffered a first vascular event after
randomization, and compared these with
the calculated extents of exposure to risk
of suffering one. (Analysis of the total
number of vascular events in each group
would be less satisfactory, as the chance
inclusion of one patient who suffers
several events might affect the totals
undulv.)
If there are 2 or more definite events
that might be adopted as " endpoints "
(e.g. time to first rejection episode and
time to complete graft failure, in the
M1RC trial of therapy following renal
transplantation, or time to relapse and
time to death in leukaemia), then it is
usuallv worth making a completelv
separate analvsis of the whole trial for
each endpoint of interest.
29.-Remi&ion duration
If time is measured from the date of
remission, analogous analyses of re-
mission duration are possible.
Exactly analogous techniques can be
used to studv the duration of remission,
if the trial time is taken to start at
remission and to end at c;relapse or
death without relapse" rather than at
death. If the randomization is done
before the state of remission is achieved,
the time at which the phvsician declares
that a patient is in remission may depend
on the particular treatment regime that
the patient will receive in remission, and
this could bias the results. It is therefore
preferable, if possible, not to randomize
until remission has been achieved, and
then to study time from randomization,
as before. If this is not possible, a very
strict definition of remission and relapse
is needed in order to communicate the
results to other workers and to avoid any
possibilitv of biased assessment. It is a
general rule that randomization should
always be left to the last possible moment
before the start of treatment, so that
events between randomization and treat-
ment do not bias or obscure the effects
of the treatments.
Moreover, it should alwavs be borne
in mind in analvses of remission duration,
that a treatment mav prolong the first
remission without prolonging survival (as
in the immunotherapy trial described
in the next section) if the delaved relapse
is more likelv to be refractorv to treatment.
(Against this, the observation that " first
remission duration and survival duration
are strongly correlated" is sometimes
made, which, although true, is not relevant
in this context.) It should also be
borne in mind that a good treatment,
which improves the chances of achieving
remission but does little or nothing to
prolong remission, mav result on average
in shorter remissions among those achiev-
ing remission, because more of the very
ill patients are being got into remission
and they might relapse more rapidly.
30.o-Cmbining information from different
trials
Different trials which each compare
the same 2 treatments may best be
pooled, to give an overall treatment
comparison, by analysing the data as
though the separate trials were each
retrospective strata within one large
trial.
Some therapeutic comparisons which
are important, but which are nevertheless
known not to involve major differences in
survival, require larger resources than
anv of the investigators who have
(CNS) which is followed by proliferation in the CNS.S partial control of the blood but not of the CNS would
prevent death from leukaemia in the blood but would allow CNS relapse to be seen. In this case a logrank
analvsis of the event " CNS relapse or death without it"' might be less misleading than a logrank analysis
of " CNS relapse , but unfortunately this safer analvsis would be less sensitive, if one treatment reallv didjust prevent or exacerbate CNS relapse, and would moreover confuse control of CNS relapse with control of
death from other causes. The same difficulties arise, of course, with all other statistical techniques, including
the apparently more straightforward visual examination of life tables.
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approached them have mustered; and
consequently many different randomized
trials of these treatment comparisons may
have been undertaken, none of which is
sufficiently accurate on its own. An
example might be the possible utility of
anti-coagulants following myocardial in-
farction, or the utility of a particular
form of immunotherapy for a particular
neoplasm. We might hope to find an
overall tendency for patients given A
to fare slightly better than patients given
B, obscured or enhanced in each particular
trial by random variation.
The most efficient unbiased way of
determining whether this is so is to
ignore in each particular trial all patients
allocated to treatments other than A or
B, and then to calculate, for each separate
trial, 0 and E for Treatment A and 0 and
E for Treatment B. Finally, we combine
the trials by adding all the O's for Treat-
ment A, to get an overall OA, all the E's
for Treatment A, to get an overall EA,
and similarly we obtain a combined OB
and EB: OA + OB wil equal EA + EB,
of course. Comparison of OA with EA
and OB with EB in the usual way, by
computing X2 = (OA-EA)2/EA + (OB-
EB)2/EB and using the analogy between
X2 and chi-square with one degree of
freedom, will lead to a P-value testing
whether A and B are statistically signifi-
cantly different from each other. Calcula-
tion of R = (OA/EA)/(OB/EB) will, more-
over, yield a useful pooled estimate of the
ratio of the death rate on A to that on B.
This method of pooling different trials
treats each trial as though it were a
retrospective stratum in a single large
trial, and of course would be equally
applicable if some of the separate trials
were themselves actually subdivided, e.g.
into young patients and old patients,
with calculation of the O's and E's
comparing treatments occurring entirely
within separate strata in each separate
trial. (A standard alternative is to pool
different trials by mathematically com-
bining the P-values from the separate
trials, but this is less sensitive.) It is
an advantage of reporting logrank O's
and E's when publishing clinical trials,
that the efficient combination of different
studies is then straightforward.
EXAMPLES
31.-Example I. Immunotherapy of acute
leukaemia
In 1968, Mathe and his co-workers
reported that of 20 patients with acute
lymphoblastic leukaemia in remission who
were subsequently given immunotherapy,
8 achieved long-term remissions, whereas
none of an untreated control group of 10
such patients did so (Mathe et al., 1969).
Eight of the 20 patients treated by
immunotherapy had received BCG alone,
and it appeared that this was as effective
as the other immunotherapy regimens
of blast cells alone or BCG combined with
blast cells. Animal work had shown
that in mice BCG can, under certain
circumstances, cure grafted isogeneic
leukaemias, and it was hoped that this
might be the first news of the break-
through to a real leukaemia cure. How-
ever, approximate comparison with con-
temporary British experience suggested
that, although the treated patients had
fared fairly well, the controls had fared
much worse than was normal, and that
this accounted for much of the disparity
between the 2 treatment groups. It was
therefore decided that the Medical
Research Council should organize a clinical
trial to assess these claims made for BCG.
If BCG has any effect, first remissions in
which BCG is given regularly should on
average last longer than first remissions
in which no treatment is given; and the
trial as originally conceived was to
compare unmaintained and BCG-
maintained first remissions.
The intake to the trial was to consist
of children with acute lymphoblastic
leukaemia who had undergone a standard
5-month course of intensive cytotoxic
therapy from their time of diagnosis.
After this course, maintenance therapy
with methotrexate was expected to pro-
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long the first remission, but possibly to
make relapses, when they occurred, more
refractory than if no maintenance treat-
ment had been given. (Some leukaemic
relapses occurring during unmaintained
remission can be controlled by drugs,
while others are refractory. If the effect
of maintenance treatment during remission
is chiefly to suppress those relapses which,
had they occurred, could have been
controlled anyway, then only the re-
fractory relapses will break through.
This effect must be allowed for in the
comparison of drug maintenance with
immunotherapy-only maintenance, before
claims that " immunotherapy in remission
facilitates the control of subsequent re-
lapses " can be made.) It appeared,
therefore, an open question whether a
patient in remission should be left alone
or given maintenance chemotherapy.
However, some physicians felt un-
happy about not including a maintenance
methotrexate group in the trial, and the
trial as finally agreed, therefore, had 2
" control " groups, a no-treatment group
and a methotrexate group. At each
centre, 2-way randomization between im-
munotherapy and control was used, but
which regimen to use for all their control
patients was chosen by each centre before
the trial began. Intake began in January
1969 and continued to August 1970.
An individual trial cannot exist in
isolation. It will of necessity last some
years, even if intake only lasts one year,
and during this time reports from other
workers may make the trial irrelevant,
and may even make its continuance
unethical. This is a major problem,
and must be considered very carefully
before starting a trial (Pike, 1973).
About one year after the start of this
trial, reports from the United States
showed that the extent to which first
remission was prolonged by maintenance
methotrexate was far greater than had
been supposed. The physicians from
centres which had chosen the no-treatment
control now felt that they should no longer
put patients into this group. It was
therefore decided that all control patients
entered from that time onwards should
receive maintenance methotrexate as their
control treatment. This detracted from
the uniformity of the series of patients,
but was in the circumstances unavoidable.
One advantage of the fact that 5
months of standard cytotoxic therapy
preceded the allocation to different treat-
ment groups in this trial was that all the
" difficult " patients (those who had
" bad " veins, refused in-patient treat-
ment, were unable to tolerate the intensive
therapy, or were not in remission 5 months
after first treatment) were eliminated
from the trial before randomization. The
group available for randomization was
therefore more than usually homogeneous:
this generally has the effect of increasing
the chances of detecting any differences
between the treatments. This uniformity
was, however, marred to some extent by
the dose of L-asparaginase given in the
intensive treatment phase being reduced
after the first 50 patients, as the original
dose level was proving too toxic and too
expensive. This could perhaps have
been avoided, had the protocol been tried
out more extensively on a pilot basis
(MRC, 1971b) just to study its toxicity.
Because of the great interest generated
by Mathe's group's results, the trial was
analysed at several different times. As
we have explained, this is in principle
a bad practice, but in this case it was
inevitable. These analyses were initially
limited to the overall comparison of the
3 treatment groups. To our disappoint-
ment, it was soon apparent that the effect
of BCG was, if positive at all, only
slight. However, since our BCG therapy
protocol differed from the French in
possibly important ways, this finding is
of less value than it might otherwise have
been.
Ideally, one should use an identical
protocol if one wants to test a published
claim, but this was not possible, partly
due to difficulty in obtaining the Pasteur
Institute vaccine used by the French;
partly due to unwillingness to scarify
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large areas of skin, as they had done,
rather than use percutaneous inoculation
by Heaf gun; and partly because 7
different protocols were used by the
French, each on 2, 3 or 4 of the immuno-
therapy patients. In retrospect, dif-
ferences between the MRC protocol and
the French protocols meant that the
negative result eventually found in our
trial is not sufficient to demonstrate that
their methods were not effective. How-
ever, another, still larger, trial (Heyn
et al., 1975) based on Mathe's report has
also produced a null result.
In the MRO trial, 191 cases presented,
122 went into remission and were ran-
domized as intended at Month 5, and a
further 10 were randomized later, during
the next few months. When, in 1971,
half the patients had relapsed (though
few had died), the results among the 122
were reported (MRC, 1971b). People
who have cited this publication have given
less prominence to the fact that there
was no statistically significant difference
between the first remission durations of
the group given BOG and those of the
untreated control group, than to the fact
that the observed median remission dura-
tion, an unreliable statistic, was 27 weeks
on BCG and 17 weeks on untreated con-
trol. However, partly because this dif-
ference diminished as more data accumu-
lated, the remission durations have never
been properly reported since. The trial
was not a critical test of immunotherapy,
because prophylactic treatment of the
central nervous system was so inadequate
that meningeal relapses prematurely termi-
nated many of the remissions, but since
on 1 January 1976 only 3/55 children
given immunotherapy were still in first
remission (compared with 2/20 given no
maintenance and 8/57 given methotrexate)
BCG given in this way appears to be of
little value (Table VI).
In Table VI, the fourth line confirms
that there is little difference between
BCG and untreated control, since the
relative relapse rates are so similar
(1.25 and 1.32).
If the data for relapses in the BCG
and untreated control groups are pooled,
the combined relative relapse rate is
1-27: (52 + 18)/(41.58 + 13.61). The
relative relapse rate on methotrexate is,
by comparison, only 0-77, confirming that
maintenance methotrexate really did pro-
TABLE VI.-MRC Immunotherapy (" Concord ") Trial: Follow-up on 1 January 1976
BCG maintenance
(55 patients)
0 E O/E
First relapse or death
in first remission
(a) WBC* 0-5 18 11-56 1-56
(b) WBC* 6-20 18 14-02 1-28
(c) WBC* 21+ 16 16-01 100
Total (a) + (b) + (c) 52 41-58 1-25
(i.e. numbers of relapses
and total extents of
exposure to risk of
relapse stratified
retrospectively
for WBC)
Methotrexate
Untreated control maintenance Total
(20 patients) (57 patients) (132 patients)
0 E O/E 0 E O/E 0 E
6
7
5
18
3-62 1-66
5 - 72 1 -22
4-28 1-17
13-61 1-32
17
15
17
49
25-82 0- 66
20 - 27 0 - 74
17-71 0-96
63-80 0 77
41
40
38
119
41-00
40-00
38 -00
119-00
Death
Numbers of deaths 39 39-46 0-99 15 15-05 1-00 40 39 49 1 -01 94 94-00
and total extents of
exposure to risk of death
within WBC strata
* Whits blood count at presentation, in units of 10 9/1. Among people in full remission, the original WBC
is still a good indicator of how long the remission might last, and among people diagnosed years ago, the
original WBC is a useful predictor of future risks of death.
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long first remissions (x2 7-41, d.f.-
1, P < 0.01), a result which was reported
in the 1971 paper. However, examination
of the life tables (not given) and the last
line of Table VI, where the relative death
rates are all unity, shows that, in the long
run, the group given methotrexate
maintenance did not survive any longer.
This result has so far not been reported,
partly because the treatments given after
relapse were so various as to defy summary,
but also, unsatisfactorily, because it is
null.
An interesting feature of the effect of
methotrexate on relapses is that the lower
the initial WBC, the greater the im-
portance of methotrexate. The 3 ratios
of the relative relapse rate of the metho-
trexate patients to the combined relative
relapse rate among BCG plus unmaintained
control patients in Table VI, were 0-42
(WBC 0-5), 0'58 (WBC 6-20), and
0 93 (WBC 21+). In other words,
among patients presenting with lower
WBCs, methotrexate can apparently
roughly halve the relapse rate, while
among patients presenting with high
WBCs, methotrexate seems to have almost
no delaying effect on relapses. When,
as here, the relative merits of 2 treatments
are very different in different strata,
there is said to be an interaction between
strata and treatments. This particular
interaction has been noticed in other
studies, and deserves investigation.
32. Example II. The MRC myelomatosis
trials
By 1964, it was generally agreed that
both cyclophosphamide and melphalan
were useful drugs for treating patients
suffering from myelomatosis. No random-
ized comparison of them had, however,
been made and a trial to compare daily
oral administration of the 2 agents was
begun in October 1964 by the Medical
Research Council. Intake continued until
August 1968, by which time 276 patients
had been admitted. The 2 treatment
groups fared almost exactly the same,
and apart from this, the main scientific
interest of the trial has, therefore, been
the relationship between certain bio-
chemical measurements made on the
patients at admission and the survival
times (MRC, 1973).
It was known that a high blood urea
indicated renal failure, and was the major
determinant of prognosis, but the statisti-
cal techniques discussed above enabled
us to investigate a whole range of possible
explanatory factors. We found that the
apparent adverse effects of hyper-
calcaemia, osteolytic lesions, and the
presence of Bence Jones protein in the
urine, were wholly explained by their
associations with uraemia. The degree of
initial anaemia was strongly correlated
with prognosis, and as expected, this
correlation was by no means completely
accounted for by the strong association
between uraemia and anaemia. How-
ever, one entirely unsuspected factor-
the serum albumin-was found to be of
substantial prognostic significance, inde-
pendently of the urea level (Table VII).
This table is based on 258 of the total
of 276 patients entered (18 patients with
unusual paraprotein types were excluded
from this analysis). The difference be-
tween the relative death rates of 1.3
and 0 4 for the low and high albumin
patients with no evidence of renal failure,
represents a difference between about
18 months and 5 years in median survival
time, and is thus of considerable medical
significance. The reason for this dif-
ference remains obscure. It has been sug-
gested that it might be that the more
dangerous myeloma cell populations
actually catabolise albumin much more
rapidly, but this suggestion has not been
properly investigated. Likewise, the
reason for the relevance of anaemia to
prognosis requires investigation, to see
whether the relevant anaemia is chiefly
of renal origin or due to bone marrow
failure.
In the second MRC myelomatosis
trial, daily low-dose cyclophosphamide
was compared with intermittent high
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TABLE VIJ.-First MRC Myelomatosis Trial
Relative death rates by initial serum levels of urea and albumin
Medium
Low albumin High All albumin
albumin (30-39 g/l) albumin levels
Low urea 1-3 0-8 0 4 0'6
(no evidence of renal failure)
Medium urea 1*8 1*0 0*9 1*1
(40-79 mg/100 ml)
High urea 3 * 8 4*4 2*1 3*2
(evidence of severe renal failure)
All urea levels 1*8 1.1 0*7 1.0
(necessarily)
doses of melphalan, and with intermittent
high-dose melphalan plus prednisone.
Because 3 treatment alternatives were
being compared, a large number of
patients was required, and intake lasted
from 1968 to 1975, which is an undesirably
long time. Three hundred and seventy-
three patients were followed up to 1
July 1976. No significant difference
between the 3 treatments emerged, but
the intermittent melphalan plus predni-
sone group did fare a little better. Since
intermittent melphalan plus prednisone
is as acceptable as intermittent mel-
phalan alone, and more acceptable than
continuous cyclophosphamide, it can be
definitely recommended, even though its
superiority was not statistically significant.
In the second trial, we again found a
statistically significant relationship
between albumin and prognosis, but it
was a weaker relationship than had been
observed in the first trial. This slight
disappointment should have been antici-
pated; moderately strong relationships
are often more extreme in the studies
where they were first discovered to be
interesting than in subsequent studies.
This is because a relationship which is in
expectation only moderate may, in various
different studies, appear weaker than it
should or stronger than it should, and it is
the latter studies which generate interest.
(For the same reason, promising new treat-
ments should not be expected to live up
to their early promise.)
We now have extensive initial data,
and various numbers of years of follow-up,
on a total of over 600 myeloma patients,
all treated fairly equivalently. Some of
the associations with prognosis (particu-
larly that of anaemia) are proving easier
to investigate in this larger series than in
the first trial series alone. As far as
prognostic correlates and their in-
terpretation are concerned, though, the
chief need now is not for still larger
numbers, nor for other workers to check
our findings on other, probably smaller
series, but for new and preferably strikingly
different therapeutic strategies to be
proposed and tested, and for new factors
to be measured in future patients. Since
1975, these have been the aims of the third
MRC myelomatosis trial.
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APPENDICES
APPENDIX 3.-Worked Example of a Clinical
Trial Analysi8 (Hypothetical Data)
Suppose that for each patient, we know
the date of randomization, the date of death
if he died before the follow-up date of 31 May
1974, the randomized treatment (A or B),
and the renal function (I = impaired, or
N = normal) at the time of randomization.
Some hypothetical data of this type are set
out in Table VIII, along with the derivation
from them of the trial time. We shall
study the relevance of treatment to death
from the disease or from causes that might
well be correlated with the disease or its
treatment, and so we shall not include the
death due to a road accident in our analysis.
If we wanted to study total mortality, of
course, we could easily count this one death
and modify the calculated extents ofexposure
to risk on Day 2240 after randomization
accordingly.
Notes on the culatik n of trial times in
Table VIII
(a) If a patient dies after randomization,
but before treatment could be started, that
is irrelevant: include him as though he had
been treated. (To avoid such occurrences,
do not randomize until the last possible
'minute.)
(b) If a patient changes treatment for
serious medical reasons, for social reasons, or
even at a doctor's whim, that is also irrelevant:
include him as though no deviation had
occurred, and try to ensure that as few
such changes as possible occur in the next
clinical trial you design. The anaylsis will
then try to answer: " Is it better to adopt a
policy of Treatment A if possible, with
deviations if necessary, or a policy of Treat-
ment B if possible, with deviations if
necessary, for patients who seem to have this
disease?" This is a relevant question,
sometimes even more relevant than " Is A
or B better for this diease? "
(c) If, during the course of the treatment,
it is realized that the original diagnosis was
erroneous, it may be decided that such
patients should stay in the analysis as if no
mistake had occurred (see the discussion
surrounding Fig. 2 on p. 602 in Part I of this
report), even if treatment has to be com-
pletely altered to attack the real disease.
(d) If causes of death are available for aU
patients who die, it may be decided that
deaths from causes which could not possibly
be related to the disease or its treatment will
be ignored, and that such patients will be
R. PETO, M. C. PIKE ET AL.
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analysed as though they had emigrated alive
on the day of their death.
(e) Patients who emigrate or are lost to
follow-up have trial times which run up to
their date of disappearance.
(f) Ignore deaths after the chosen follow-
up date, and be certain that no deaths before
this date have escaped your notice.
(g) It is slightly preferable to calculate
trial times accurately to the nearest day,
especially if mortality shortly after entry is
very rapid, although weeks or even months
are often sufficiently accurate units of time
if computing facilities are not available.
(Leap years can be dealt with most con-
veniently, if using a computer or calculator
to derive days from dates, by altering the
month and vear so that January and
February become months 13 and 14 in the
previous year. The number of leap-days to
be counted for a date is then the number of
times 4 can be divided into the corrected
year, and allowance for the irregular lengths
of months need make no special allowance
for February.)
Now arrange the patients in order of
increasing trial time. (If there is a tie, put
patients who suffered a relevant event on
that day just before patients who did not.)
This is done in Table IX, where the life
table and extents of exposure to risk of
death are calculat-ed. The life table
calculated in Table IX appears as Fig. 5.
From Table IX, we obtain:
OA = observed no. of
deaths in Group A = 6
EA = extent of exposure to risk of
death in Group A 8-34
OB = observed no. of
deaths in Group B = 11
EB = extent of exposure to risk of
death in Group B = 8-66
(At this point of the calculation, check for
arithmetic accuracy by seeing thatOA + OB
- EA + EBR)
Calculate
X2 (OA-EA)2 (OB-EB)2EA EB
1-29
Because we are comparing 2 groups with
each other, it is appropriate to compare X2
with the chi-square distribution with mean
one. When we do so, we find that the
probability of getting a value of chi-square
3
with 1 degree of freedom as big as or bigger
than 1-29 is quite substantial (about 1 in 4),
which suggests that the apparent superiority
of Treatment A could well have arisen by
chance alone.
However, before accepting this conclusion
let us first study the relevance of renal func-
tion to prognosis. This requires an extra
4 columns of numbers to be added to the
right of Table IX, and these are given as
Table X.
From Table X:
OI observed no. of deaths among those
with renal impairment = 7
EI extent of exposure to risk of death
among those with renal impairment
=1-60
ON = observed no. of deaths among those
with normal renal function = 10
ENs extent of exposure to risk of death
among those with normal renal
function = 15-40
and so
(01-E1)2 (O-EN -2
El + EXEN) 20-12.EI E~N
Since the probability of getting a value of
chi-square with 1 degree of freedom as big
as or bigger than 20-12 is < 0-001, the
tendency of those with renal impairment to
die sooner cannot plausibly be merely due to
chance. This indicates that we should
examine the treatment differences separately
among those with and without renal im-
pairment, and this is done in Tables XI and
XI.
From Table XI, among patients with
impaired renal function, GA 4, EA _ 5-42,
OB =3, and EB= 1-58.
From Table XII, among patients with
normal renal function, OA= 2, EA = 5-01,
OB =8, and EB= 4-99-
Combining the observed numbers and the
extents of exposure to risk of death in both
prognostic categories:
OA= 4 + 2 =6
EA = 5-42 + 5-01 = 10-43
OB = 3 + 8 - 11
EB 1-58+4-99=6-57
Because we have now allowed for the
overwhelmingly strong effect that renal
condition has on prognosis, the effect of
treatment on prognosis stands out more
clearly. This is because, by retrospective
31
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TABLE X.-Extension of Table IX to Study the Relevance of Impaired Renal Function to
Pronosis
Numbers alve and at risk
Extent of Expore to Risk of
Death
in impaired
= e.i/r
0-560
0-261
0-227
0-190
0-150
0-211
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Sum = 1-599
in normal
= e.nfr
1-440
0- 739
0-773
0-810
0-850
1-789
1
1
1
1
1
1
0
1
1
0
1
0
0
0
0
0
0
Sum = 15-401
stratification, our analysis now only com-
pares like with like, instead of mixing all
sorts of different patients blindly together
as before. Using the above observed num-
bers and the extents of exposure calculated
within prognostic strata, we now have:
X2 (6-10.43)2 (11-6-57)2
10-43 + 6-57
4-87,
and referrinrg to the chi- square distribution
appropriate for a 2-group comparison (i.e.
chi-square with 1 " degree of freedom "),
we find that 0-025 < P < 0-05. The
difference in prognosis between the 2 groups
is therefore statistically significant (X2
4-87, d.f. = 1, P < 0-05), although only
marginally so.
After adjustment for the effects of renal
condition on the extent of exposure to risk
of death, the relative death rate in Group A
is 0-58 (6/1043), that in Group B is 1-67
(11/6-57), and so the ratio of the death rate
on Treatment A to that on Treatment B is
0-34 (0-58/1-67). In other words, the death
rate observed on A is about one-third of
that on B, although the vast uncertainty
attached to this as an estimate of medical
fact is emphasized by the fact that this
extreme ratio is only just significantly
different from unity!
If you have a statistician analysing your
data for you, he may use your O's and E's
to calculate something slightly different from
your X2 to compare with the chi-square
distribution (Peto and Pike, 1973; Breslow.
1975-see statistical notes 7 and 8 on p. 38),
However, the answers you will obtain by the
simiple analogy between X2 and the chi-
spare distribution will give an adequate
medical understandingo of the data. As was
noted on p. 20, a convenient computer
program is available on request which will
perform all the analyses described in Appen-
dix 3.
APPENDIX 4.-Hotw to Record Data in Such a
Way that it i8 Easy to Analyse by Computer
(a) Computers like to read data one line
at a time, each line containing up to, but not
more than, 80 characters (letters, digits,
blanks, dots, etc.). Computers like to tell
what a number denotes, simply by which
position it occupies in the line (e.g. the 43rd
character), so omission of a blank can shift
e, from
Table IX
1
1
1
2
1
1
1
1
1
1
10
1
0
0
0
0
0
r, from
Table IX
25
23
22
21
20
19
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
i = no.
impaired
7
6
5
4
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
n = no.
normal
18
17
17
17
17
17
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
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PROLONGED CLINICAL TRIALS. II: ANALYSIS
all subsequent numbers one space leftwards
and cause chaos. It is not humanly possible
to feed in data as carefully as this, unless
you first write out the data on a coding form.
Fig. 7 illustrates a coding form used in a
recent MRC trial. Although the coding
form illustrated was designed to be com-
pleted by the physician referring the patient,
it is usually preferable to ask the physician
to complete a form designed with his
convenience and understanding chiefly in
mind, and to copy this on to a computer
coding form at the trial centre. This keeps
him as co-operative as possible, and forces
you to check that all requisite information
has been supplied. (Immediate queries of
missing or doubtful information are better
than queries during the statistical analysis a
year or two later.)
(b) On the coding form, there are a given
number of boxes for each item of information,
and the information is written in, one
character per box. Although the boxes are
all on different lines on the coding form,
before they are fed into the computer,
they will all be concatenated into a single
line, giving all the data for that one patient
(unless that makes more than 80 boxes,
in which case the line will be cut up at certain
points into 2 or more lines per patient, each
80 or less characters in length).
(c) Apart from the boxes reserved for
the patient's name, in which you will write
a mixture of letters and blanks, try to use
nothing but digits and blanks-no letters,
Surname
(first 10 letters only, if long:
Sex (1 M, 2 F)
Date randomized (d, m, y)
and no dots. This will make the pro-
grammer's task a little easier. For example,
if you want to record a patient's sex, have
a box for doing so, but adopt the coding
convention 1 for male and 2 for female
instead of entering M or F. Also, if you
want to record a number with a decimal
part, leave out the dot and just give the
figures (115 for 11-5 and 110 for 11-0, for
example). Everything that has a decimal
part must be given to the same number of
decimal places, even if the decimal part is
zero.
(d) Computers do not like to distinguish
between blank and zero. This has two
consequences. Firstly, if nothing is written
for a piece of information, the computer
will read it as though zero were written
there. (If, therefore, zero is a possible
value, it is usually better to have an im-
possible number that can be entered to
denote " no data ", and when defining how
replies about something are to be recorded
as a number, it is better not to have zero
as one of the codes.) Secondly, if someone
has a pair of boxes in which to enter the
number 9, he must write it in the right-
hand box: if he wrote it in the left-hand box
of the pair, the computer would take the
number written in that pair of boxes as
being 90!
(e) Never underestimate the number of
characters required for recording something.
For example, if a number might possibly, just
for one patient in the whole trial, run into 3
1I' IR.I'/VI 1 1 A1 I I I
wH
I |b| I I 1 1W1
Hb at presentation
(g/100 to one d.p., omitting the point)
Leucocytes
(000/pl: enter 999 if not known) I I ESi
etc.
(So far, 23 characters have been used; this form actually ran to
68 characters in all.)
FiG. 7. Part of a coding form.
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digits (e.g. age), then allow 3 boxes for it.
It does not matter if, in the event, the
left-hand box is never used.
APPENDIX 5.-Testing for a Trend in Prognosis
with Respect to an Explanatory Variable
Frequently, if a group of patients is
divided into more than 2 subgroups with
respect to an explanatory variable, these
subgroups have a natural order (e.g. low%,
medium, high) and can be numbered 1, 2,
3 . . . in a non-arbitrary way. It is then
usually more sensitive, if we need to know
whether there is any relationship of that
explanatory variable to prognosis, to ask
whether there is a statistically significant
tendency for a trend in prognosis to exist
as we go from Group 1 to Group 2 to Group 3
(and on, if there are more than 3 groups),
instead of asking if there is statistically
significant heterogeneity (by calculation of X2,
as on page 31). There are a few situations,
however, where there could be real hetero-
geneity but no real trend; for example,
average patients might fare better than
patients who are extreme in either direction,
up or down. The best general policy, when
examining the relevance to prognosis of an
explanatory variable which is split into 3 or
more naturally ordered subgroups, should
therefore be to calculate both the test for
trend (described below) and the X2 test for
heterogeneity. However, the P-value ulti-
mately used to help infer whether this explan-
atory variable is at all related to prognosis
should nearly always be based on the test for
trend, rather than on that for heterogeneity,
even if the statistical significance of the
heterogeneity test is slightly more extreme
than that of the test for trend.
Computational details. The test for trend
involves these steps:
(a) Divide the patients into subgroups
with respect to the explanatory variable.The
choice of the number of subgroups is not
usually critical, except that if it is small it is
slightly preferable for it to be odd (e.g. 3 or 5)
rather than even. It is usually best to aim
to have roughly similar numbers (to within
a doubling) in each subgroup, although this
is not essential, and if medical considerations
suggest particular natural groupings, especi-
ally of a non-continuous explanatory variable
such as disease stage, these should be adopted.
(b) Give each subgroup a number,
starting at 1 and working upwards in natural
order (e.g. low urea - 1, medium urea = 2,
high urea = 3).
(c) For each subgroup count 0, the
observed number of events, and calculate E,
the extent of exposure to risk of such events,
according to the methods described in
Section 19. Add up the O's to obtain
Osum and the E's to obtain Esum, and
check that, apart from rounding errors,
Osum = Esum. If not, there is an arith-
metical error in the derivation of the O's or
the E's. (Note that Esum is simply the total
number of patients in the whole trial who
have suffered an event.)
(d) Calculate X2, the test statistic for
heterogeneity, as the sum of (O-E)2/E, as
in Section 20.
(e) In each subgroup we now have n,
the subgroup number, and the logrank 0 and
E for that subgroup. Calculate, within
each subgroup:
A
B
C
n(O-E)
nE
n2E
(f) Add up all the A's in the different
subgroups to obtain " Asum ". Analogously
obtain " Bsum " and " Csum ".
(g) Calculate V where V= Csum-
(Bsum x Bsum/Esum) (see statistical note 9
on p. 38). Finally, calculate T, the test
statistic for trend, where
T = Asum x Asum/V.
(If T is negative or exceeds X2 you have
made an arithmetical error somewhere: if
Osum and Esum are equal after step c, there
must be an error in step d, e, f or g.)
(h) Obtain a P-value by using an analogy
which exists between the behaviour of T
if the explanatory variable is in fact irrelevant
and the behaviour of one of the standard
distributions in statistics, called " chi-square
on 1 degree of freedom" (see page 10).
This implies that if the explanatory variable
is irrelevant (so there is no real trend), then
T is zero or positive, and would be expected
to be around unity
T has an approximately 3 chance of exceeding
unity
T has an approximately 10% chance of
exceeding 2-71
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T has an approximately 5% chance of
exceeding 3-84
T has an approximately 21% chance of
exceeding 5-02
T has an approximately 1%1 chance of
exceeding 6-63
T has an approximately 4 O/o chance of
exceeding 7-88
T has an approximately 04001 chance of
exceeding 10-83.
For example, if we computed T = 4-32 in a
particular case, we might insert, in our
published account of the data, " Chi-square
test for trend vielded 4-32; d.f. = 1: P <
0-05."
Example: data from Table V are displayed
in Table XIII, with derivation from them
of the requisite quantitie3.
Now V 567-52 - 320-28 x 320-28/213-00
= 85-93
and T = 79-72 x 79-72/85-93
- 73-96
(Check: Osum - Esum and zero < T < X2.)
If initial urea were irrelevant to prognosis,
the probability that, by chance alone, T
would exceed 10-83, is approximately 04001,
so the probability in this case that T should
equal or exceed 73196 is much less than
0-001. We would therefore write ' Chi-
square test for trend yielded 73-96: d.f. = 1
P < 0-001."
Incidentally, in a test for trend between
just 2 groups of patients, so that n = 2,
T will necessarily just equal X2.
STATISTICAL NOTES
As in Part I, these are collected together
so that they can be completely ignored by
the non-statistical reader. The statistical
methods recommended in this paper are
developed in Kaplan and Meier (1958),
Mantel (1966), Peto (1972), Cox (1972), and
Pet4o and Pike (1973), and are reviewed by
Breslow (1975).
STATISTICAL NOTE 6.-(From p. 6). If the
life table at a particular time after randomi-
zation equals L, and there are then N
patients still at risk, the standard error of L
at that time is approximately LV((1 - L)/N).
(Example: suppose that at one year after
randomization there are 20 survivors still
being observed, and the life table estimate
of the chance of surviving one full year from
randomization is 0-2. The estimated
standard error of the life table at one year
would then be 0-2 x /(0-8/20), which is
0-04.)
The justification for this formula is that
there must initially have been at least N/L
patients for N to remain when the life table
equals L. If originally there were exactly
N/L, binomial theory yields the standard
error estimate L/((1 -L)/N). If there were
more than N/L originally, the life table will be
somewhat more accurate than this, depending
on the trial times of the surviving patients.
This estimate is therefore usually conserva-
tive, although the actual degree of con-
servatism is often surprisingly slight, and is
counterbalanced by the fact that the formula
deals appropriately with the increasing
uncertainty that should properly be expected
as one goes along the long flat region with
which many life tables finish. The Green-
wood standard error estimate (Kaplan
and Meier, 1958) is less immediately com-
puted, and has the disadvantage that in
such life table tails, which are often the
regions of greatest medical interest (and the
source of most mistakes), the standard error
may be grossly underestimated. Whichever
estimate is preferred, the trial times of the
surviving patients should somehow be
indicated with the plotted life table as in
Figs. 3, 4 and 5.
TABLE XIII.-Test for Trend in Prognosis with Respect to Initial Blood Urea Among
Patients Entered into the First MRC Myelomatosis Trial (From Table V)
Initial urea
(mg/100 ml
blood)
0-39
40-79
80-
Group
number,
n
1
3
Totals
Names of totals:
0, observed E, extent of
no. of exposure to
deaths risk of death
79 122-06
81 74-60
53 16-34
213 213-00
Osum Esum
(O-E)2
E
15-19
0-55
82-25
97-99
X2
A=
n (O-E)
-43-06
12-80
109-98
79- 72
B=
n E
122-06
149-20
49-02
320-28
Asum Bsu
C=
n'E
122-06
298-40
147-06
567-52
Csuim
37
R. PETO, M. C. PIKE ET AL.
STATISTICAL NOTE 7.-(From p. 11). For a
2-group comparison, the variance, V, of
(OA -EA) can be computed. It is the same
as the variance of (OB -EB), of course, and
is obtained by arguing that, for those alive
and observed in the trial on each particular
day, a 2 x 2 table giving group membership
(A or B) and fate that day (died or not) can
be constructed. The variance of the differ-
ence between observed and expected for the
number of Group A deaths in each such
table can be calculated, and since OA-EA
is the sum of all such differences V is the
sum of all such variances. On a day when
there are a A-patients and b B-patients at
risk and the observed survival rate among
both groups of patients combined is p, the
contribution to the overall variance V will be
p(l -p)ab/(a + b -1).
Finally, (OA-EA)2/V (or, if a continuity
correction is preferred,* (GOA-EAII )2/V)is referred to tables of chi-square with one
degree of freedom. If the continuity cor-
rection of 1 is not used, this is necessarily
greater than or equal to X2. If more than 2
groups are to be compared a variance/
covariance matrix from each day must be
accumulated to give the overall variance/
covariance matrix for the vector of the
(O- E)'s in each group, but the principle
is similar. Details are given by Peto and
Pike (1973) and an example is given in
Appendix 3.
There is a strong connection between
these methods and those of Cox (1972) for
comparing 2 groups. Cox uses /3 to denote
the log of the ratio of the hazard functions
in the 2 treatment groups. He then derives
a log-likelihood L(:) and uses the statistic
L'(0) to test = 0 noting from likelihood
theory that its variance must be approxi-
mately -L"(0). In the absence of tied
ranks L'(0) and -L"(0) are the logrank
(O- E) and its variance V, giving a deeperjustification to logrank methods.
STATISTICAL NOTE 8. (From p. 33). In this
particular example, where OA= 6 and
EA= 10-43 one might use the methods
described in the statistical note 7 to compute
V -variance of (OA -EA)= 3.39, leading
to a chi-square of 4-432/3-39 = 5-79 without
a continuity correction, or, if a continuity
correction is preferred, (4 43 -)2/3.39
4*56.
STATISTICAL NOTE 9.-(From p. 36). The
approximation is being made that under the
null hypothesis Asum has mean zero (which
is exactly true) and variance V (which is not).
The exact variance, Vexact, of Asum may be
obtained by noting that, if xi denotes the
* Continuity correction. With more than 2 groups, a continuity correction is definitely unwanted, but
there is no uniform practice of using or not using a continuity correction when comparing 2 groups by the
logrank test, and the reasons why are quite interesting. Two fundamentally different methodls may be
available for deriving the P-value from the calculated values of 0 and E in each group, the permutational
method (Peto, 1972) or the conditional method (Mantel, 1966). If there are initially a Group A subjects
and b Group B subjects, then both methods calculate a P-value given the times from randomization at which
deaths occur and given the durations of follow-up of those who do not die. The permutational P-value,
Pperm, is the probability that if a of the a + b patients were selected at random and taken as Group A, the
remainder being taken as Group B, a value of (O-E) as extreme as or more extreme than that actually
observed would then be generated. The conditional argument considers the information in the data to be
equivalent to that in a hypothetical set of independent 2 x 2 tables, one for each post-randomization day
with margins equal to the margins of the 2 x 2 tables actually observed relating death on that day to
group membership among those still at risk on that day. The conditional probability, P,ond, is then theprobability that the value of (O-E) obtained by combining a set of such 2 x 2 tables in the usual way
would be as extreme as or more extreme than the observed (O -E).
The permutational argument is usually applicable when two groups being compared have been separated
by randomization, and is then preferable because Pperm will usually, although not always, be smaller than
Pcond. The variance of (O-E) under the permutational argument is approximately V, and since there
are usually many permutations that would lead to values of (O-E) very close to, buit not, equal to, the
value of (O-E) actually obtained, Pperm is usually better estimated if a continuity correction is not used.
The conditional argument lacks a little of the efficiency of the permutational argument, but leads more
naturally into Cox's (1972) methods, and into the study of treatment effects in particular time-periods.
However, since it leads us, albeit slightly artificially, to regard E as fixed and 0 as an integer-valued random
variable with variance exactly V, P0ond is usually better estimated if a continuity correction is used.
The conditional argument is always valid, but the permutational argument is sometimes not (e.g. if we
compare survival among 2 groups of patients which have on average been followed up for different lengths
of time). Nevertheless, when comparing the efficiency of the logrank test with that of alternative statistica
tests for detecting differences between randomized groups, the efficiency of the permutational argument
should be used.
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value of (O -E) in the ith subgroup, Asum =
Eixi and the Vexact is EXijcij, where summa-
tion is over all groups from first to last inclu-
sive and cij, the covariance of xi with xj, is
given by Peto and Pike (1973). A preferable
test for trend, albeit one which is not acces-
sible without statistical expertise, is then to
take Asum2/Vexact (or, if a continuity cor-
rection is preferred, (IAsum -0-5)2/Vexact) as
chi-square with 1 d.f. There is a strong con-
nection between this recommended test for
trend and the methods developed by Cox
(1972). These methods test for trend by
attempting to relate the log hazard function
linearly to the subgroup number by a para-
meter f and then testing g,B 0 by examining
the log-likelihood function, L(fl). Since the
quantity Asum equals Cox's L'(0), and in the
absence of tied ranks the quantity Vexact
equals Cox's L"(O), it is therefore of full
asymptotic efficiency in a reasonable class of
models to base a test for trend on Asum.
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